

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Tel No: 0141-2228066, 2228064, E-mail: edpssrmsc@rajasthan.gov.in

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF SURGICALS (DRUG ITEMS)

(Rate Contract for the period ending on 30.09.2026)



LAST DATE OF SUBMISSION OF ONLINE BIDS: 11.07.2024 up to 6.00 PM

DATE AND TIME OF TECHNICAL BID OPENING: 12.07.2024 at 11.00 AM

मुख्यमंत्री निःशुल्क दवा योजना



RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, SwasthyaBhawan, Tilak Marg, Jaipur – 302005, India

Phone No: 0141-2228066, 2228064 Website: www.rmsc.health.rajasthan.gov.in E-mail: edpssrmsc@rajasthan.gon.in

Ref. No.: F.02 (175)/RMSCL/Proc./S&S (MD)/NIB-12/2024/3642 Dated:-19.06.2024

Notice Inviting E-Bids

E-bids for rate contract cum empanelment for supply of following item (s) are invited from

eligible bidders:-

S. No	Item Name /Descripti on	Ref. No	UBN	Estimated Value in Rs.	Last Date Of Submission Of Online Bids
1.	SURGICALS (DRUG ITEMS)	F.02 (175)/RMSCL/Proc./S&S (MD)/NIB-12/2024/3642 Dated:-19.06.2024		Rs 6.87 Cr.	11.07.2024 Up to 6.00 PM

Other particulars of the bids may be visited on the procurement portal http://eproc.rajasthan.gov.in, http://eproc.rajasthan.gov.in, http://eproc.rajasthan.gov.in, and www.rmsc.health.rajasthan.gov.in and may.rayarthan.gov.in and www.rmsc.health.rajasthan.gov.in and may.rayarthan.gov.in and ma

Executive Director (Procurement) RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD., RAJASTHAN

E-BID FOR THE CONTRACT CUM SUPPLY AND EMPANELMENT OF SURGICAL AND SUTURES (Rate Contract for the period ending on 30.09.2026)

Bid Reference F.02 (175)/RMSCL/Proc./S&S (MD)/NIB-12/2024/3642

Dated:-19.06.2024

Date and time for downloading bid document 20.06.2024 from 02.00 PM

Pre- bid conference 25.06.2024 at 11.30 AM

(Board room)

Last date and time of submission of online 11.07.2024 up to 06:00 PM

bids

Date and time of opening of Online technical 12.07.2024 at 11:00 AM

bids

Estimated Cost Rs. 6.87 Cr.

Cost of Bid Document Rs. 2,360/- (including GST @ 18%)

Cost of Bid Document For MSME Unit of Rs. 1,180/- (including GST @ 18%)

Rajasthan

RISL Processing Fees Rs. 2,950/- (including GST @ 18%)

Empanelment Fee (Optional) Rs. 5,900/- (including GST @ 18%)

INDEX

S.NO	PARTICULARS				
510	General instruction for bidders				
1.	Last date for receipt of bids, bid document fees, Bid Security Deposit, RISL processing fees and empanelment fees				
2.	Eligibility criteria				
3.	Purchase preference				
4.	General conditions				
5.	Technical Bid				
6.	Price Bid				
7.	Opening of Technical & Financial Bid				
8.	Opening of Price Bid (BOQ)				
9.	Production of Samples				
10.	Bid security deposit				
11.	Other conditions				
12.	Acceptance of bid				
13.	Performance Security (performance guarantee)				
14.	Supply conditions				
15.	Logograms / markings				
16.	Packing				
17.	Quality testing				
18.	Payment provisions				
19.	Deduction in payments:				
20.	Quality control deduction & other penalties				
21.	Empanelment of firms				
22.	Saving clause				
23.	Jurisdiction				
24.	Correction of arithmetic errors:				
25.	Procuring entity's right to vary quantity:				
26.	Dividing quantities among more than one bidder at (in case of procurement of goods):				
27.	Grievance redressal during procurement process:				
28.	Compliance with the code of integrity and no conflict of interest:				
29.	Fall Clause				
30.	Applicability of Rules				
	Annexure-I Bank Challan				
ده	Annexure -II (A) Form-,,A" issued by Authority				
Annexure	Annexure -II (B) Format of Affidavit				
lex	Annexure -III Annual Turn Over Statement				
	Annexure -IV Agreement Annexure - V Check List				
~	Annexure - V Check List Annexure - VI Check List of Details Regarding Products Quoted				
	Annexure - VI Check List of Details Regarding Floducts Quoted Annexure - VII Declaration & Undertaking				
	Annexure - VII Declaration & Oldertaking Annexure - VIII List of item (s) With Specifications				
	Annexure - VIII List of item (s) with Specifications Annexure - IX Guidelines for Blacklisting/Debarring of Product or Supplier/Company				
	Annexure–X Memorandum of Appeal Under The Rajasthan Transparency In Public Procurement Act, 2012				
	Annexure -XI Undertaking For Empanelment				
	Annexure -XII Supplier Consolidated Invoice				
	Annexure –XIII Analytical Report Regarding Quality				
	Annexure -XIV Security form (Bank guarantee)				
	Annexure -XV Land Border Country Registration Requirement				
	Annexure –XVI Performance Security Declaration				
	Annexure –XVII – No Deviation declaration				
	Annexure-XVIII- Bidder's Authorization Certificate				

GENERAL INSTRUCTIONS FOR BIDDERS

The bidders are instructed to carefully read the complete bid document. The following points may be noted so that mistakes/lapses/shortcomings during Bid preparation and submission can be avoided:-

- 1. It is expected from all bidders that they shall ensure that documents to be used in bid set will be given to a reliable person only, and that only a fully reliable person shall be authorized for DSC. So that the confidentiality of your bid/ rates can be maintained up to bid opening & that your documents are not put to any misuse.
- 2. In case you are given any assurance of any advantage in RMSC, by anybody or if you are directly or indirectly threatened or intimidated of harming your bidding & subsequent work in RMSC, please inform immediately about the same to MD, RMSC or ED (Proc.) RMSC. It would be better if evidence of such unfair activity of such person is produced so that action can be taken against such person / institution and their details can be put on the website.
- 3. It is advisable for you to authorize only those persons for RMSC tender who are employed in your company on salary basis.
- 4. The turnover should be as per bid conditions. Do not submit Bid if the turnover of the firm is less.
- 5. Quote only for the products for which your Product Permission meets the Bid specifications. Do not quote if it differs with regard to any parameter.
- 6. Quote rate in BOQ for the packing exactly given in annexure VIII. For example if the packing is given for 12 foils, the rate should be quoted for 12 foils for sutures, and not for 1 sutures, similarly if the packing unit in the bid specifies each piece or a unit in surgical, the rate should be for each piece or a unit in surgical.
- 7. Highlight the quoted item (s) in the documents like Product Permission and also mark the item code no. at appropriate place in the documents.
- 8. The uploaded product permission and other documents should be clearly legible. Date of issue of the documents should be clearly legible.
- 9. Upload the Bids on the e-proc portal well in advance so that failure in uploading can be avoided and no desired document remains un-uploaded.
- 10. In case there is any suggestion regarding Bid conditions/ specifications/shelf life, strength, packing/turn over etc., the suggestions should be submitted/sent/e -mailed one/two days earlier from the date of pre bid meeting so that the representation of the bidders may be well processed and decision could be taken well in time. Bidders may submit their representations within one working days after pre-bid meeting. Representations received after that would not be entertained.
- 11. One person can be authorized by represent only one bidder for a particular item. In case, it is found that one person is representing/ authorized representative of more than one bidder for a particular item than all such bidders shall be disqualified on the ground of conflict of interest.
- 12. If there is any query in Bid document/uploading process, you may contact. **Sh. Rajesh Gupta, Senior Manager (Proc)** Mob. No. 9314078838 Ph.0141-2228064 **Sh. Lokesh Bairwa, Senior Manager (Drug)** Mob. No. 9588099110 If any condition or term which is contrary to RTPP Act 2012 or RTPP Rules 2013, then provisions of RTPP Act 2012 or RTPP Rules 2013 shall prevail and be binding on bidders

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

Rajasthan Medical Services Corporation Ltd., (hereinafter referred as **Bids Inviting Authority** unless the context otherwise requires) invites E-BIDS FOR THE RATE CONTRACT CUM SUPPLY AND EMPANELMENT FOR SUPPLY OF SURGICALS (DRUG ITEMS).

1. <u>LAST DATE FOR RECEIPT OF BIDS AND BID FEES, BID SECURITY,</u> RISL PROCESSING FEES AND EMPANELMENT FEES

- (a) E-Bids in two separate bid (Technical bid & Price Bid) can be submitted till 11.07.2024 up to 06:00 P.M. on e-proc portal i.e. https://eproc.rajasthan.gov.in/, for the rate contract cum supply and empanelment for supply of Surgicals (DRUG ITEMS). (Rate Contract for the period ending 30.09.2026)
- (b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity period for an additional specified period of time. The Bidder may refuse extension of bid validity, and in such a case its Bid security deposit shall not be forfeited.
- (c) The Bids will be received on e-procurement web-portal of Govt. of Rajasthan. Every Bidder will be required to pay the following fees:
- Bid form fee Rs. 2,360.00 (including GST @18%). For MSME Units of Rajasthan) it would be Rs. 1180.00
- Processing fee of Rs. 2,950/- (including GST @18%) of R.I.S.L.
- Bid Security Deposit Bid Security Deposit shall be@2% (for MSME unit of Rajasthan @ 0.5%) of Estimated Bid value for each quoted item as per Annexure – VIII
- Empanelment fee (**Optional**) Rs.5,900/-(including GST @ 18%)

These fee are to be paid through three separate prescribed challan (format enclosed in Annexure- I) in any branch of the BANK OF MAHARASHTRA Account no.-60460019022 & IFSC Code no. MAHB0000389 throughout country on 11.07.2024 upto 06:00 PM or through D.D. / BC/ NEFT/RTGS/IMPS/ BG/ e-BG in favour of M.D. RMSCL (Bid document fees and Bid security. For bid processing fees only DD/ BC shall be accepted in favour of M.D. RISL. All D.D. / BC, copy of all the receipts, NEFT/RTGS/IMPS/BANK CHALLAN/ BG/ e-BG should be submitted physically in the office of RMSCL on 11.07.2024 upto 06:00 PM. The bidders shall submit/upload copy of all the receipts, scanned D.D./BC/NEFT/RTGS/IMPS/BANK CHALLAN/ BG/ e-BG in Technical Bid. Bids will be opened only after ensuring receipt of Bid document fees along with processing fees and Bid Security Deposit. In the absence of Bid document fees and processing fees and Bid Security Deposit the Bids will be rejected and will not be opened. The validity of Bank Guarantee/e-BG should be for 6 months from the date of issuance of BG/e-BG.

Note:- (I) deleted

- (d) Click on offline mode (either DD or BC) on e procurement portal for the purpose of bid uploading only. For Empanelment as supplier for Surgical & Sutures, bidders are required to deposit separately an Empanelment Fee (optional) of Rs 5900 (inclusive of GST @18%) (Five Thousand Nine Hundred rupees only) in the form of DD (in favour of MD, RMSCL)/challan before due time and date of bid submission. Please see clause 21 and Annexure-XI in this regard.
- (e) DD/ BC/ NEFT/RTGS/IMPS/BANK CHALLAN/ BG/ e-BG submitted by bidder should have been purchased/transferred/deposited from the account of the bidder only. If it is found that such fee have been paid from any bank account / person other than the bidder, than such fee would not be considered and such bids would be rejected.

2. ELIGIBILITY CRITERIA

- (a) Bidder should be a manufacturer having valid manufacturing license or direct importer holding valid import license. For patented / proprietary imported items manufactured outside India, Co-marketers having sole marketing rights in India are also eligible to participate. Distributors/ Suppliers / Agents are not eligible to participate in the Bids.
- (b) In Case of Manufacturer the bidder must have a valid manufacturing license issued by the State Licensing Authority / Central Licensing Authority.
- (c) In Case of Importer Bidder should have a valid import license for the quoted item (s) issued by the Central Licensing Authority.
 - Importer should also have a valid sale license (On form no. 20B, 21B also as applicable.)
- (d) Bidder must have Non-conviction Certificate issued by the State Licensing Authority/Central Licensing Authority.
- (e) Bidder must have Market Standing as per required in technical bid.
- (f) Quality certificate as per required in technical bid.
- (g) Documents for proof of experience.-
 - Bidder should have submit self attested copies of documents related to the supply of bidded item (s) in any of the hospitals of either Govt. of Rajasthan / Govt. of India /AIIMS/ PGI/ Army Base Hospital / Govt. Medical Corporation, for last continuous three years as per technical bid.
- (h) Annexure-VII as per bid document. (Declaration & Undertaking on Non-Judicial Stamp Paper of Rs. 500/-).

- (i) Bidder should have Average Annual Turnover (for Drugs & Medicines including Surgical and sutures or medical devices business) as per technical bid.
- (j) Bidder must have submitted its GST returns for the last three months form the last date of bid submission.
- (k) Bidder must have committed monthly supply of 5% of the tendered quantity for each item.
- (1) Debarring/Banned/Blacklisting/NoSQ etc.:-
 - (i) Bid should not be submitted for the item (s) for which the concern/company/firm stands blacklisted /banned/debarred on the date of bid submission either by Bid inviting Authority.

OR

The Bid should not be submitted for those products also for which the concern/company/firm stands blacklisted/banned/debarred on the date of bid submission by any other State/Central Govt. or its any agencies (central Drugs procurement agencies) on the ground of conviction by court of law or the products being found Not of Standard Quality (NoSQ).

- (ii) The concern / company / firm which stands blacklisted/banned /debarred on any ground either by Bid Inviting Authority (RMSCL) or Govt. of Rajasthan or its departments on the date of bid submission, shall not be eligible to participate in the Bid. The concern company/firm which stands blacklisted / banned / debarred on the ground of conviction by court of law or the products being found Not of Standard Quality (NoSQ) by any other State / Central Government or it's any agencies (Central Drugs Procurement Agencies) shall also not be eligible to participate in the Bid. For Specific cases regarding other quality issues the purchase committee of RMSCL may decide the case on merit basis.
- (iii) If any item (s)of a company/firm have been declared as Not of Standard quality, as per Medical Device Rules 2017/Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable, during last two year anywhere, such concern/company/firm shall not be eligible to participate in Bid for such item (s). If any company/firm is found to have any such item (s) quoted in the Bid, the bidder shall be blacklisted for 2 years for such item (s) and a Bid Security Deposit shall also be forfeited. In such situation, the bid will be considered further only if the amount of penalty is deposited before the completion of technical evaluation.

- (iv) The concern/company/firm whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court of law shall not be eligible to participate for that particular item (s) in the Bid. Similarly convicted concern/company/firm shall also not be eligible to participate in the Bid.
- **Note:** (i) The Market Standing Certificate issued by State Licensing Authority / Central Licensing Authority should not be more than 2 years old from the last date of bid submission.
 - (ii) The period of Market Standing will be reckoned from the date of issue of Product Permission.

3. PURCHASE PREFERENCE

- (i) Price Preference is not applicable as GST which had been made effective from July 1, 2017 in place of VAT.
- (ii) Purchase Preference shall be given to MSME unit of Rajasthan as per notification of Finance (GF&AR Division) Department, Govt. of Rajasthan no. S.O. 165 dated 19.11.2015.

4. GENERAL CONDITIONS

- a) At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by way of amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority can at his discretion, extend the date and time for submission of Bids.
- b) Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority, i.e. RMSCL
- c) In case any document submitted by the bidder or by his authorized representative is found to be forged, false or fabricated, the bid shall be rejected and Bid Security/Performance Security will be forfeited. Bidders or their representative may also be banned/debarred. Report with police station can also be filed.

5. TECHNICAL BID

The Bidder should furnish the following in technical bid along with copies of relevant documents:-

(a) Bidders are allowed the option to quote for anyone item or more item(s) as mentioned in bid (list of drugs and medicines proposed to be purchased at Annexure-VIII). The amount of Bid Security Deposit shall be@ 2% of Estimated Bid value for each quoted item as per Annexure – VIII

- (b) The bidders shall submit/upload scanned copy of all the copy of receipts, NEFT/RTGS/IMPS/BANK CHALLANS, D.D. / BC/BG/e-BG annexed with Technical Bid as proof of deposition/ submission of Bid document fees, RISL processing fee and Bid security. The required Bid Security Deposit / Bid document fees may be in form of physical D.D./ BC and should be in favour of M.D. RMSCL. RISL fee should be paid in form of DD/BC only in favour of M.D. RISL. D.D./ BC submitted by the bidder should have been purchased from the account of the bidder only If it is found that such fee have been paid from any bank account / person other than the bidder, than such fee would not be considered and such bids would be rejected.
- (c) Bidders which are found responsive on technical grounds would be empanelled also on submission of Annexure-XI and payment of empanelment fee of Rs. 5000 +GST@18% for supply of surgical & sutures item (s) mentioned in Annexure-VIII for one year. The empanelment would entitle a firm to participate in limited bids invited by the RMSCL. Such situations may normally arise when the open bid for surgical & sutures item (s) fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reasons. The Bidder has to submit an undertaking in the format given at Annexure –XI, The Bidder who have already paid empanelment fee earlier (within a year), need not to submit the empanelment fees for the item (s) being quoted in this bid. However the required Annexure-XI must be submitted.
- (d) Documentary evidence for the constitution of the company / firm such as Memorandum and Articles of Association with certificate of incorporation issued by registrar of companies, Partnership Deed, Self declaration on letter head in case of proprietor ship firm etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.
- (e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed.(Annexure-XVIII)
- (f) Bidder have to submit following valid licenses:-
 - (i) For Manufacturer:- The bidder must submit a valid manufacturing license issued by the State Licensing Authority/Central Licensing Authority under Medical Devices Rules 2017/Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable for each quoted item (s).
 - In case bidder has submitted expired manufacturing license, then a copy of acknowledgment of renewal application issued by the State Licensing Authority/Central Licensing Authority or copy of original treasury challan regarding manufacturing license retention fees shall also be enclosed.
 - (ii) For Importer:- In case of importers, Bidder should have a valid import license for the quoted item (s)issued by the Central Licensing Authority.

In case bidder has submitted expired Import license, then a copy of acknowledgment of renewal application issued by the Central Licensing Authority or copy of original treasury challan regarding Import license retention fees shall also be enclosed.

Importer should have to submit valid sale license (On form no. 20B, 21B also as applicable. In case bidder has submitted expired sale license, then a copy of acknowledgment of renewal application issued by the State Licensing Authority or copy of original treasury challan regarding Sale license retention fees shall also be enclosed.

(iii) For Co -marketer: Bidder should have to be submitted following documents -

- 1. Import license of principle manufacturer of patented/proprietary imported items.
- 2. Quality certificate of principle manufacturer of patented/proprietary imported items.
- 3. Sale license of co-marketer firm.
- 4. Non conviction certificate of both firms i.e. importer and co-marketer firm.
- 5. Market standing Certificate for quoted item as per tender conditions.
- 6. Market standing Certificate of co-marketer firm as per tender conditions.
- 7. Undertaking that the Co-marketing firm shall be accountable towards all responsibilities/ liabilities as per tender terms and conditions and fulfill all such requirements.
- (g) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary documents related to each manufacturing unit shall have to be submitted as a separate set with the same Bid. A bidder shall be allowed to submit only one offer for one bidded item.
- (h) Manufacturing / Import license having permission in brand name of quoted item (s) may also be accepted.
- (i) Bidder have to submit **Marketing Standing** of the bidded item (s) as below:-
 - For Manufactured Item (s):- Bidder must have Market Standing Certificate for last three calendar /financial years from the last date of bid submission, issued by the State Licensing Authority/Central Licensing Authority under Medical Devices Rules 2017/Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable for the quoted item (s)from the last date of bid submission.
 - For item (s) which have not completed three years after obtaining license under Medical Device Rule 2017 (class A and Class B item (s), the market standing of three years shall be established on the basis of records of manufacturing and sales (CA certificate with UDIN no.) shall be furnished by the bidder.
 - Bidders who have obtained license under Medical Device Rule 2017 (class A and Class B item (s) but have not completed three calendar /financial years, then they have to submit MSC issued by the State Licensing Authority/Central Licensing Authority for completed calendar / financial year from the date of issuance of such license for that period. For the period prior to issuance of license the MSC issued by a CA based on the basis of records of manufacturing & sales with UDIN number for remaining period to complete the three years market standing may be considered.

For imported item (s):-

- (1) The importer should have at least 3 year standing as manufacturer/importer of drugs in general.
- (2) In the case of imported products, the product should have minimum 3 years standing in the market.
- (a) <u>Bills of lading / Bills of entry and Sale invoices for last three calendar /financial years.</u>

OR

(b) Market Standing Certificate issued by the Central Licensing Authority under Medical Devices Rules 2017 for last three calendar /financial years.

OR

- (C) Market standing for the product in international market would be considered for establishing eligibility regarding this particular clause of the bidding document. Also if a bidder is manufacturing a product abroad at various locations/countries and participating in the bid quoting a product being manufactured at a particular place, market standing of the product manufactured at other than particular place would be considered. Market Standing for the quoted item (s) in international market issued by competent authority of manufacturing country / country of origin or Bills of lading / Bills of entry and Sale invoices for other than manufacturing country / country of origin for last three calendar /financial years should be submitted. If submitted bills of lading / bills of entry and sale invoices are issued in other than English language than verified translated (in English language), self attested copies of the same should be submit along with original ones.
- (j) Bidder must submit Non-conviction Certificate issued by the State Licensing Authority/Central Licensing Authority for all manufacturing licenses / Import licenses as mentioned in Annexure VII. In case of Importer firm, Non-conviction certificate issued for all sale licenses (as mentioned in Annexure VII) of firm may also be acceptable. Submitted Non-conviction Certificate should be recent and not more than one year old form the last date of bid submission.
- (k) **Quality Certificates:** Following valid quality certificate should have to be submitted. The certificate should not be older than one year from the last date of Bid submission in case validity is not mentioned in the certificate.

The Firm should have to hold Quality Certificate for the product during entire rate contract. If Quality certificate expires during the currency of contract, it is firm's responsibility to inform RMSCL about the same and not to accept any further purchase order till re-issue /renewal of Quality certificate. During the period of non validity of Quality certificate of the firm the rate contract will deemed to be suspended. If the firm fails to inform RMSCL about the expiry of Quality certificate and accept purchase order of RMSCL and later on it comes to the knowledge of RMSCL, in such situation firm shall be liable for a panel action. Product of the firm shall be liable to be debarred for a period of atleast two years from the date of order.

- a) For manufacturer:- In case bid is being submitted under Medical Devices License, there is no requirement of WHO-GMP/GMP/QMS (ISO 13485). (If any requirement of quality certificate mentioned specifically in the tender for quoted item (s) then the bidder must submit the same.)
- b) For importer: The Importer should produce a valid quality certificate which is at par with WHO-GMP like US- FDA/ four digits notify CE certificate / Quality Management System (QMS) of their principal manufacturing company sites (Plant) issued by the concerned authority of the exporting country. (If any requirement of quality certificate mentioned specifically in the tender for quoted item (s) then the bidder must submit the same.)
- (l) <u>Documents for proof of experience.:-</u>

Bidder should submit self attested copies of following documents related to the supply of bidded item (s) in any of the hospitals of either Govt. of Rajasthan / Govt. of India /AIIMS/ PGI/ Army Base Hospital / Govt. Medical Corporation, for last continuous three years:-

- (i) work order/ purchase order
- (ii) GSTIN invoices
- (iii) Challan receipt

At least one work order/ purchase order, GSTIN invoices and challan receipt for each year from the last date of bid submission)

- (m) Brochure/Technical Catalogue/IFU with detailed specifications of the quoted item(s) shall be submitted. **Item (s) code and catalogue number should be highlighted in the product literature.**
- (n) In case of proprietary item (s) of a particular firm / bidder, the bidder should submit its proprietary certificate along with detail of validity period.
- (o) Bidder must submit a No Deviation Declaration (with respect to the specifications mentioned for quoted item/ item (s)) to be given on letter head, as per Annexure XVII. In case, there is any deviation it should be mentioned in such declaration.

- (p) Alternative Item(s)/Models/Brand/Quality shall not be permitted. Bidders are required to quote only those item (s) for which proposed Item(s)/model/brand/quality meet to the specifications as mentioned in the tender document for particular item(s).
- (q) Average Annual turnover (for Drugs & Medicines including Surgical and sutures or medical devices Business) in the last three financial years.

Average Annual turnover (for Drugs & Medicines including Surgical and sutures or medical devices Business) in the last three financial years [2019-20, 2020-21 & 2021-22 or 2020-2021, 2021-2022 & 2022-2023 (Audited Final Accounts)] for surgical shall not be less than Rs. 10 Crore and for MSME Units of Rajasthan, the average annual turnover in the last three financial years [2019- 20, 2020-21 & 2021-22 or 2020-2021, 2021-2022 & 2022-2023 (Audited Final Accounts)] shall not be less than Rs. 5 Crore.

The same should be supported by audited annual accounts & certified by a Chartered Accountant, based on audited accounts.

No provisional accounts shall be accepted/considered.

Annual Turnover Statement without UDIN number shall not be considered.

Explanatory Note:-

The merger / amalgamation / transfer of business / transfer of assets of a firm affect the bid condition relating to 'Turnover'/ 'Past Performance' / 'Market Standing Certificate' in preceding years. The eligibility of a bidder in this regard shall be ascertained by the Purchase Committee on the basis of the above stated agreement / BOD resolution / CA certificate or any other document(s) / certificates which shall be annexed with the tender documents.

- (r) Details of GST registration. The industries situated in GST free zones will produce the copy of appropriate notification. Bidders has to submit GSTIN number and state where GSTIN registered for every quoted item (s) for which supply will be made (Annexure VII at point no.3)
- (s) GST returns file of last 3 month from last date of bid submission.
- (t) Undertaking (as in Annexure-VII) for embossment of logo on packing of surgical and sutures as the case may be, as per conditions specified at Clause 15 herein.
- (v) The bidder who are manufacturing firm should have its own in-house testing laboratory wherein all the tests required with respect to the quality standards of quoted products are carried out. An undertaking be submitted in Annexure-VII.
- (w) Undertaking that the manufacturer has not been debarred/banned, the product never been declared as Not of Standard Quality (NoSQ) during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure- VII.

RajKaj Ref 8172015

- (x) List of item (s) quoted to be shown in the **Annexure- VII** point number 6 with license number (manufacturing/Import/Sale license) written on it.
- (y) A Checklist (**Annexure-V**) for the list of documents enclosed with their page number. The documents should be serially arranged as per **Annexure-V**. Every bidder shall also be required to submit details of product permission of the quoted item (s) and the desired market standing, in **Annexure-VI**.
- (z) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document and quoted item (s) confirm all parameters of specification and required standards to be submitted in **Declaration & Undertaking (Annexure-VII point no.12)**
- (aa) Certificate that bidders with beneficial ownership from countries sharing land border with India, for participation in any public procurement in the State, shall only be allowed after prior registration with the authority as per Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021.
- (ab) A copy of PAN issued by Income Tax Department, GoI

Note:-

• The bidder must highlight the quoted item (s) in submitted documents to support the technical evaluation of the bid.

Special Note to bidder :-

- 1. Bidders are again advised to fill the Annexure VII very carefully as after bid opening any amendment in Annexure-VII would not be allowed in any case. Bidders should ensure that self certified copies of all relevant documents i.e. Product Permission, Quality certificate, Market standing certificate, Non Conviction Certificate should be in accordance with the license no. / Product Permission mentioned in the Annexure VII. Bids Submitted without duly filled Annexure-VII would be declared Non-Responsive.
- 2. Bidders who fail to submit copies of documents as under, would summerly declared as non-responsive:-
- (a) In case copies of Product Permission either not submitted or not as per tender conditions/specifications of the item; If Product Permission is as per specifications of item mentioned in the tender but it's for export purpose, the Product Permission for domestic manufacturing would be accepted only when asked through clarification and provided that such Product Permission for domestic manufacturing has been issued on or before the last date of bid submission.

- (b) If copies of quality certificates and/or Non-Conviction certificate and/or Market Standing Certificate have not been submitted in main bid or not as per tender condition/item specifications. It has also been observed that in certain cases, licensing authority takes time in issuance / renewal of aforesaid certificates, in such cases bidders have to invariably enclose expired documents/certificates along with copy of acknowledgment of application for renewal of such documents filed with licensing authority. In such cases bidders would be allowed to submit renewed documents at the time of clarification sought by the RMSCL, provided that the renewed documents should have been issued on or before the date of submission of clarifications as sought by the RMSCL.
- (c) If licenses (Manufacturing/Import/Sale) have not been submitted in main bid or not as per tender requirement/ item specifications. It has been also been observed that in certain cases, licensing authority takes time in issuance/ retention of aforesaid licenses, In such cases, bidders have to invariably enclose expired licenses (Manufacturing/Import/Sale), Then a copy of acknowledgment of renewal application issued by the State Licensing Authority/Central Licensing Authority or copy of original treasury challan regarding (Manufacturing/Import/Sale), license retention fees shall also be enclosed.

6. PRICE BID

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the mentioned packing unit only.

7. OPENING OF TECHNICAL AND FINANCIAL BID

- (a) The Technical Bid will be scrutinized by Bid evaluation committee.
- (b) Technical Evaluation of the Bid will be done in two stages.
- (c) (i) Technical Evaluation of the Bid will be done on the basis of documents submitted by the bidder.
 - (ii) If required RMSCL may ask for the samples of bided item (s) and so for Evaluation / Examination / Testing of samples by an expert team/approved empanelled laboratories. (May be done for as per requirement) Bids of the item (s), samples of which are not found as of standard quality and/ or do not match the request specification would be declared as rejected / non-responsive.
- (d) Price Bid (BOQ) of the Bidder found eligible on satisfying the criteria for technical evaluation, will only be opened.

8. EVALUATION OF SAMPLES

Procuring entity may call for the samples of bided item (s) for a physical evaluation of the item (s) by an expert committee in such case only those firms would be declared responsive whose samples are approved by the expert committee and financial bid would be open only for those responsive.

9. **BID SECURITY**

The Bid Security shall be @ 2% of Estimated Bid value for each quoted item as per Annexure – VIII.In case Bid Security submitted by the bidder is Less than the required bid security as per total no. of quoted item (s) the quoted items by the bidder will be counted in sequence up to the number matching the Bid Security deposited.

Bid Security will not be taken from undertakings, corporation of GoI & GoR. Further, Bid Security will be taken @ 0.5% of Estimated Bid value for each quoted item as per Annexure – VIII from MSME Units of Rajasthan. They will furnish copy duly attested by gazetted officer of the registration of MSME units of Rajasthan issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs. 100 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II(B)).

The Bid Security shall be paid through separate prescribed challan (format enclosed in Annexure-I) in any branch of the BANK OF MAHARASHTRA Accountno.-60460019022&IFSCCodeno.MAHB0000389 throughout country upto 11.07.2024 or through D.D. / bankers cheque in favour of M.D. RMSCL or may be given in the form of bank guarantee (e-BG) also in specified format of a schedule bank in case the amount exceed Rs. 5 Lac. For amount of up to Rs. 5 Lac, it should be deposited through DD/BC/Challan/NEFT/RTGS/IMPS. The validity of bank guarantee/e-BG should be for 6 months from the date of issuance of BG/e-BG.

DD/BC/BG/e-BG, copy of all the receipts, NEFT/RTGS/IMPS/Bank Challan/ should be submitted physically in the office of RMSCL on or before 11.07.2024 upto 6.00 PM. Bid security Deposit in any other form will not be accepted.

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the performance security. Other actions would also be taken as per RTPP Act 2012 & Rules 2013 and guidelines for blacklisting/debarring of RMSCL.

10. OTHER CONDITIONS

- (1) The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (herein after referred to as Ordering Authority).
- (2) The details of the required Surgical and sutures are shown in Annexure-VIII. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination. The commitment quantity for an item submitted by the bidder (in Annexure VII) shall be taken into account. The whole commitment quantity to be supplied during contract period should not be less than estimated bid quantity. As well, the monthly commitment quantity should not be less than 5 % of the whole commitment qty. A bidder having manufacturing capacity less than commitment quantity (either monthly or for whole contract period) may be technically disqualified.

- (3) Bid has been floated with the **generic names** of Surgical and sutures. The Bidders should quote the rates for the generic products. **However the supply with brand name shall be accepted without penalty.** The composition and strength /Size of each product should be as per details given in Annexure-VIII. Any variation, if found, will result in rejection of the Bid. The products should conform to the specified standards IP/BP /USP/BIS/CE marked/US FDA approved etc. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.
- (4) Free on DDWs/MCDWs Rates (inclusive of <u>all expenses / charges but exclusive of GST</u>) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.
- (5) (a) To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders.
 - (b) Orders will be placed periodically during rate contract period based on the RMSCL's requirement to the firms approved for rate contract as per above clause no. 3 above.
 - (c) After the conclusion of Price Bid opening, the lowest offer of the Bidder is considered for negotiations and rate arrived after negotiations is declared as L-1 rate and L-1 supplier for an item of Surgical and sutures for which the Bid has been invited.
 - (d) The Bidder who has been declared as L-1 supplier for certain item or item (s) of Surgical and sutures shall execute necessary agreement for the supply of the Bided quantity of such Surgical and sutures as specified in the Bid document on depositing the required amount performance security and on execution of the agreement, such Bidder is eligible for the placement of purchase orders. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.
 - (e) RMSC will inform the L1 rate to the Bidders who qualified for Price Bid opening, through RMSC web site or e-mail; willing bidders may inform in writing their consent to match with the L-1 rate for the item of the surgical and sutures quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.
 - (f) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, **GST** etc.) of price (L-1 rate).

- (g) The supplier, on receipt of the purchase orders finds that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform to the RMSCL immediately without loss of time and the purchase orders shall be returned within 7 days from the date of the order, failing which the supplier is stopped from disputing the imposition of liquidated damages, fine for the delayed supply.
- (h) If the L1 supplier has failed to supply /intimated RMSC about his inability/delay in supply as per the purchase order, the required Surgical and sutures within the stipulated time or as the case may be, RMSC may also place purchase orders with the Matched L-1 rate Bidder for purchase of the Surgical and sutures provided such rate matched Bidders shall execute necessary agreement indicating the production capacity as specified in the Bid document on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or item (s) of Surgical and sutures quoted by them.
- (i) Subject to para (h) above, while RMSC has chosen to place purchased orders with Matched L1 supplier and there are more than one such matched L1 supplier, then the purchase orders for the requirement of Surgical and sutures will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.
- (j) The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.
- (k) The supplier shall supply the ordered quantity as per the delivery schedule of P.O. before the stipulated period from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happens to be a holiday, the supply should be completed by 5.00 p.m. on the next working day.
- (6) The rates quoted and accepted will be binding on the Bidder during validity period of the contract and any increase in the price (except increase in GST rate or any other statutory taxes) will not be entertained.
- (7) No Bidder shall be allowed to claim revision or modification of bid after opening of bid. If any bidder withdraws or modifies its bid after opening of bid the bid security taken from the bidder shall be forfeited. Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids. Conditions such as "SUBJECT TO AVAILABILITY" "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.

- (8) Supplies should be made directly by the bidder and not through any other agency.
- (9) The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the item (s) quoted. If a Company/Firm does not allow for any such inspection, its Bids will be rejected. *The firms/companies selected to supply the quoted product /products may be inspected within 3 months after entering into contract with the firm.*

11. ACCEPTANCE OF BID

- (1) The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
- (2) Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more item (s) of the surgical and sutures Bided for in a Bid without assigning any reason.
- (3) Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the currency of Bid and also has the right to reject the Bid or terminate/cancel the purchase orders issued and or not to reorder, based on adverse reports brought out during such inspections.
- (4) The acceptance of the Bids will be communicated to the successful Bidders in writing/through E-mail by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit performance security and the agreement within 15 days from issuance of Letter of Acceptance.
- (5) The approved rates of the successful Bidders would be valid as Rate contract and ending on 30.09.2026 (w.e.f date of letter of acceptance) and may extend up to 3 months, without any given prior intimation and required mutual consent, if required.
- (6) Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

12. PERFORMANCE SECURITY

The Successful Bidders shall be required to pay performance Security Deposit @ 5 % of the Contract value. Performance security will not be taken from undertaking, corporation of GoI & GoR. They have to submit a declaration as per Annexure-XVI for performance security. The MSME Units of Rajasthan shall be required to pay Performance security @ 1% of the contract value.

The performance security shall have an upper limit of Rs 25 Lac to be deposited by a bidder at the time of signing of agreement (For one or many item). However, when the actual purchase orders cross a threshold for requiring additional security, the same will be required to be deposited by the supplier.

The performance guarantee should be paid upfront in respect of each contract on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee or electronic bank guarantee (e-BG). (Performa given in Annexure XIV) in case the amount exceeds Rs. 5 Lac. For amount of upto 5 Lac. it should be deposited in the form of demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure-1 (the validity of bank guarantee should be for a period of thirty six month from the date of issuance of Bank Guarantee) in favour of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur before releasing the purchase order by the ordering authority. In case Rate Matched Bidders who have agreed to supply at L-1 price, then the performance security Deposit of such bidders will be 5% of value of quantity fixed for them. (upper limit Rs 25 Lac). Performance Security shall remain valid and refunded 60 days beyond the date of completion of all contractual obligations or after 36 months from the date of issuance of letter of acceptance, whichever is later.

13. AGREEMENT

- a. The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days period from the date of Letter of acceptance / Letter of intent or within extended period by the Bid Inviting Authority, i.e. the Managing Director, Rajasthan Medical Services Corporation Ltd. The Specimen form of agreement is available in Annexure-IV. Failing to submission of performance security and execution of agreement within stipulated period as above, will result in forfeiture of Bid Security Deposit & other consequential action. A bidder who is found successful in more than one product; he will be intimated through LOA / LOI to execute agreement for all the products / drugs / items. If such bidder will not execute agreement for one or more items, in such situation Bid security of that item shall be forfeited and the product for which agreement is not executed shall be debarred for a period of not less than 3 years as per guidelines for blacklisting/debarring of RMSCL.
- b. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
- c. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

13 SUPPLY CONDITIONS

(a) Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Surgical and sutures and will be supplied at 34 District Drug Warehouses (DDW) at Districts Head Quarters of Rajasthan and 6 Medical Colleges, warehouses of Rajasthan).

- (b) Purchase orders will be placed on the successful Bidder at the discretion of the Ordering Authority.
- (c) The supplier shall supply the entire ordered quantity before the end of **60 days** from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSC, the supply should be completed by 5.00 p.m. on the next working day. For Surgical item (s) requiring sterility test and imported ones, the supply period will be **75 days** from the date of issue of purchase order.
- (d) All supplies will be scheduled for the period from the date of purchase order till the completion of the tender in installments, as may be stipulated in the purchase order.
- (e) The Bidder must submit its Test/Analysis report for every batch of item along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of item will be returned back to the suppliers and he is bound to replenish the same with approved lab test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied.
- (f) The item (s) supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents.
- (g) If supplies are not fully completed as per stipulated delivery schedule in 60 days from the date of the Purchase Order, (75 days for surgical requiring sterility test/imported item (s)) the provisions of liquidated damages of Bid conditions will come into force. The Supplier should supply the Surgical at the Warehouse specified in the Purchase Order and if the *item* (s) supplied at designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.
- (h) If the supplier fails to execute at least 50% of the quantity mentioned in a Purchase order and such part supply is come into existence in 3 purchase orders during the currency of Contract period, then supplier shall be liable for debarment for the particular product for 2 years. Two years period will be reckoned from the date of issuance of such debarment order.
- (i) If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the item for which the Purchase orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Tender inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.

- (j) The order stands cancelled after the expiration of delivery period, if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the Performance Security and shall invite other penal action like debarring/disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. (as per Guidelines for blacklisting/ debarring at Annexure- IX)
- (k) It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.
- (1) If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause, on a specific request made by the Bidder before expiry of supply period, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes etc. Reasons must be beyond control of supplier.
- (m) The supplier shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Bid Inviting Authority in any trade or business or transactions nor shall the supplier give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Customs" or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.
- (n) If the supplier, or any of its approved item (s) gets debarred/banned/blacklisted in any state after entering into agreement with RMSC, it shall be the responsibility of the supplier to inform RMSC without any delay about the same
 - i. The firm shall inform to the RMSC within 15 days of issuance of the blacklisting / banning / debarring order. If the firm does not inform, then 2% penalty shall be levied on the purchase orders issued between the date of issuance of blacklisting / banning / debarring order to the date of submission of clarification, both dates inclusive, shall be imposed, subject to a maximum penalty of Rs 20000 and a maximum penalty up to Rs.200000 only.
- (0) If it is brought to the notice of RMSC that the similar drug of the supplier firm has been found spurious / adulterated in any other state (whether the firm / product has been blacklisted/ debarred/ banned or not); then no further purchase orders shall be issued for the product and the rate contract with the firm for the product shall be cancelled.
- (p) Shelf Life: The labeled shelf life of item supplied should be not less than the period mentioned against each item in list of item (s) (Annexure-VIII). The remaining shelf life of the surgical at the time of delivery should not be less than ¾ of the labeled shelf life.

RajKaj Ref 8172015 (q) Quality Assurance: The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of specifications and related documents (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purpose made; (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per applicable standards. In case of imported item (s) the remaining shelf life of 60% or more may be accepted with an undertaking that the firm will replace the unused expired stores with fresh item (s). However, firms supplying Surgical with remaining shelf life of 75% or more need not submit such undertaking.

The protocol of the tests should include the requirements given in applicable standards and those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of surgical along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of item will be returned back to the supplier who is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied.

(r) If a supplier does not supply any quantity against two successive purchase orders than supplier shall be liable for debarment for the particular product for one year, one year period will be reckoned from the date of issuance of such debarment order.

If a supplier fails to execute first order, without proper justification, a show cause notice may be given to him to respond within 7 days. If it does not respond or does not give reasonable justification, the corporation may order to L-2 and L-3, for entire failed supply on L-1 matched rate. If L-2 and L-3 matched rates are not available, then only purchase may be made on 'Risk and cost basis' as being done presently. Subject to other condition of Bid documents.

(s) If the supplier fails to execute full supply of the quantity mentioned in a purchase order then a penalty of 15 % of Value of unsupplied quantity shall be charged. Cases of zero supply against a purchase order shall also be dealt with in same manner.

15. **LOGOGRAMS / Markings**

Logogram means, wherever the context occurs, the design as given below:-

DESIGNS FOR LOGORAMS

Surgical to be supplied with the following logogram and with the word "Rajasthan Govt. Supply- Not for sale निःशुल्क वितरण हेतु QC – Passed" overprinted and the following logogram in which will distinguish from the normal trade packing. Name of surgical should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



SPECIMEN LABEL FOR OUTER CARTON

RAJASTHAN GOVT. SUPPLY NOT FOR SALE

Name of Surgical/Suture

CONSTITUENTS OF.....

Name of the Surgical/Suture, Manufactured by, Batch no Mfg. Month & year, Exp. Month & year, (Shelf Life) Quantity

Net. Weight......Kg
Manufactured by:
Date of Sterilization...
Mfg/Import License No

The name of the Surgical and sutures shall be mentioned in Hindi and English and should be legible and be printed prominently. A uniform colour theme and artwork will be necessary. Apart from this "For Govt. of Rajasthan – Not for Sale निःशुल्क वितरण हेतु। QC – Passed" along with logo of RMSCL will be printed on each item.

- 1. Bids for the supply for Surgicals shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the labels as per the design .All containers have to be supplied in standard packing as required with printed logogram. Affixing of stickers and rubber stamps shall not be accepted.
- 2. Failure to supply Surgicals with the logogram will be treated as breach of the terms of agreement and damages will be deducted from bills payable as per conditions in Clause 18.2. Bidders who are not willing to agree to conditions above will be summarily rejected.
- 3. In case of imported surgical, affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

RajKaj Ref 8172015

- 4. In case of Sterilized Medical Devices, the date of sterilization may be given as date of manufacturing of the device.
- 5. If the medical device is made up of stable material such as stainless steel, titanium and supplied non sterile, the date of expiry may not be necessary.
- 6. Label may bear symbols recognized by BIS (Bureau of Indian Standards) or ISO (International Organization of Standards).
- 7. In case of small size medical devices on which information cannot be printed legibly shall include the information necessary for product identification and safety.
- 8. Label may bear RMSCL item code number.

16. PACKING

- (a) The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
- (b) It should be ensured that only first hand fresh packaging material is used for packing. All packaging must be properly sealed and temper proof.
- (c) All packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia/BIS /Act.
- (d) The name of the surgical should be printed in clearly legible bold letters (It is advisable that the colour of font be different from other printed matter to make the name highly conspicuous.
- (e) It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
- (f) All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act
- (g) Packing should be able to prevent damages or deterioration during transit.
- (h) In the event of item (s) of surgical and supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item (s) of surgical and for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.2 and 22.

(i). SCHEDULE FOR PACKAGING OF SURGICAL GENERAL SPECIFICATIONS:-

- (1) No corrugate package should weigh approx 15 kg. (i.e. product + inner carton + corrugated box).
- (2) All item (s) should be packed only in first hand strong boxes only.
- (3) Every corrugated box should preferably of single joint and not more than two joints.
- (4) Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.
- (5) The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 degree should not crack.

(6) Every box should be sealed with gum tape running along the top and lower opening.

(j) CARRY STRAP:

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

(k) LABEL:

- (1) Every corrugated box should carry a large outer label clearly indicating that the product is for "Rajasthan Govt. Supply-Not for Sale".
- (2) The Product label on the cartoon should be large at least 15 cm. x 10 cm. dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

(I) OTHERS:

(1) No box should contain mixed products or mixed batches of the same product.

17. QUALITY TESTING

- (1) Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSC will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
- (2) The Surgical shall have the desirable properties within the permissible level throughout the shelf life period of the Surgical. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
- (3) In the event of the samples of the Surgical supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of item (s) of Surgical for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.
- (4) The supplier shall furnish to the purchaser the evidence of bio-availability and/or bio-equivalence / other parameters for certain products when asked for. If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
- The domestic manufactured products should have ISI mark, for the item (s) which are not ISI mark should at least conform to the standards of IP/BP / USP/BIS as the case may be for which laboratory test may be done along with clinical examination with reference to the standards laid down in the protocol. In case, the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported item respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP).

(6) The supply of any item shall be considered complete for the purpose of calculation of liquidated damages only when reference standards/ standard testing procedure or test protocol/placebo materials are made available to the corporation along with the supply of item (s) as per the purchase order. However these materials and documents shall be made available by supplier to Quality Cell of RMSC Headquarter. Such requirement will however be indicated in the purchase order.

18. PAYMENT PROVISIONS

- (1) No advance payment towards costs of Surgical will be made to the Bidder.
- (2) On receipt of the consolidated invoices (Annexure-XII) duly stamped & signed by authorized signatory, consignee receipt and analytical report regarding quality (Annexure-XII & XIII), the payment would be made as soon as possible.
- (3) The in charge of District drug warehouse (DDW) will be required to acknowledge the surgical received & ensure entry in e-Aushadhi software online.
- (4) All bills/ Invoices should be raised in <u>triplicate</u> and in the case of excisable Drugs and Medicines; the bills should be drawn as per <u>GST Rules / other applicable Rules</u> <u>if any</u> in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW/<u>MCDW</u>.
 - a. In house test report of drug.
 - **b.** The challan / invoice copy pertaining to DDW/ MCDW
- (5) Payments for supplies will be considered after receipt of reports of standard quality on samples having been tested approved laboratories of ordering authority.
 - (a) Payments can be initiated if 50% supply has been made against a purchase order by a supplier before expiry of supply period/ extended supply period.
 - (b) After expiry of supply period/ extended supply period payments for actual supplies made against a purchase order will be made although supplies are less than 50%.
- (6) If at any time during the period of contract, the price of Bided item (s) is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.

In case the price of a surgical fixed by NPPA (Govt. of India) under applicable DPCO is less than the RMSC contract price, the supplier shall be bound to make the supplies of such item (s) at price fixed by the Govt.

(7) (a) In case of any enhancement in <u>GST as per</u> notification of the Government after the date of submission of Bids and during the Bid period, the quantum of additional <u>GST</u> so levied will be allowed to be charged extra as a separate item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in <u>GST</u>, the Bidder should produce a letter from the concerned Excise authorities / <u>GST authorities</u> (<u>Central and State</u>) for having paid additional <u>GST</u> on the goods supplied to ordering authority and also must claim the same in the invoice separately. <u>In case of reduction in rates of GST price will be reduced accordingly.</u>

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt. (Including NPPA), after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

- (b) In case of successful bidder has been enjoying <u>GST</u> exemption <u>or</u> any criteria of Turnover etc., such bidder will not be allowed to claim <u>GST</u> at later point of time, during the tenure of contract, when the <u>GST</u> is chargeable on goods manufactured/<u>Supplied</u>.
- (8) (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.
 - (ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.
 - (iii) Extension in delivery period:- In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-
 - (a) Delay upto one fourth period of the prescribed delivery period; 2.5%
 - (b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
 - (c) Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
 - (d) Delay exceeding three fourth of the prescribed delivery period. 10%.
- Note 1: Bidder should apply for extension before expiry of original supply period mentioned in purchase order. No request will be considered after the expiry of supply period.
- Note 2: Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.
- Note 3: In specific condition, permission for additional delay of 10 days may be granted for supply, in such a case an additional penalty of 5% shall be levied.
- Note 4:- If a supplier seeks extension in supply period beyond two times the time indicated in purchase order, the supply period shall be extended with the condition that if the rate received in new bid(s) invited is lower than the rate contract in operation, then the supplier shall be entitled to the lower rates so received.
- (9) If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, wars, fire, storm, tempest or other exceptional cause, on a specific request made by the Supplier, the time for effecting delivery may be extended by the Purchaser surely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.
- (10) If the firm is Blacklisted/Debarred by State Govt. of Rajasthan during rate contract period/ after rate contract period, the firm has to follow below mentioned conditions:-
 - > Further Purchase orders should not be placed to firm.
 - > Purchase orders in process shall be cancelled.
 - ➤ All unconsumed stock from DDWs should be lifted on the cost of firm.
 - > If payment is made for unconsumed stock it should be recovered from firm.
 - > All rate contracts should be cancelled.

19. **DEDUCTION IN PAYMENTS:**

- (a) If the supply is received in damaged conditions it shall not be accepted.
- (b) All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No..

20. QUALTIY CONTROL DEDUCTION & OTHER PENALTIES:

- (a) If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Bid security Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from **debarring** the supplier. (As per guidelines for debarring at annexure IX including amendment)
- (b) If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action against it and the entire stock in such batch should be taken back by the supplier within a period of 30 days of the receipt of the letter from ordering authority. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF STANDARD surgical ITEM (S) LISTED UNDER MEDICAL DEVICE RULES 2017 IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy the NOT OF STANDARD surgical drugs ITEM (S) within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the Surgical rejected till such destruction. The supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority.
- (c) The supplier will not be entitled to any payment whatsoever for Item (s) of Surgical found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of surgical from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for debarring. (As per guidelines for debarring at annexure IX including amendment)
- (d) For supply of Surgical of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including debarring/banning. (As per guidelines for debarring at annexure IX including amendment)
- (e) The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied surgical etc., shall be final and bidding.
- (f) Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.

- (g) For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per PDR Act or other rules.
- (h) Non performance of any contract provisions shall be examined and may disqualify the firm to participate in the future Bids.
- (i) In the event of making ALTERNATIVE PURCHASE, as specified in Clause 14(i), Clause 16(h) and in Clause 17.3 the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the Performance Security or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier and provided further that such amount to be levied as per penalty from supplier on account of non-supply shall not be less than 15% of the value of non-supplied even when rates in alternative purchase method are lower / equivalent to rates in original tender
- (j) In all the above conditions, the decision of the Bid Inviting Authority, viz. Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding, in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
- (k) All litigations related to the supplier for any defaults will be settled by Bid Inviting Authority and his decision will be final and binding. A approved bidder may request to appoint an arbitrator to decide a dispute. Fees and other charges payable to arbitrator shall be borne by both parties equally.
- (1) In the case of litigation as per court decision/award by arbitrator, if any amount of interest is payable/receivable etc. then RMSC will charge interest@9% per annum simple interest and it will be payable @ 6% per annum simple interest only.

21. EMPANELMENT OF FIRMS (Optional)

RMSC invites Applications from eligible firms for Empanelment for supply of Sutures (listed in Annexure- VIII) for two years. The empanelment would entitle a firm to participate in RMSC for limited tenders. Such situations may normally arise when the open tender for Surgical & Sutures fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.

The empanelment can be renewed for the next one year term on payment of the empanelment fee as applicable at the time of renewal.

22. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

23. JURISDICTION

In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench only).

24. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

- (i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;
- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited.

25. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:

- (i) At the time of award of contract, the quantity of Surgical & originally specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The tender quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period.
 - The supplier shall submit the supply commitment quantity in **Annexure VII** at point no 3 which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.
- (ii) If the procuring entity does not procure any subject matter of procurement or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.
- (iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSC. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.

26. <u>DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS)</u>:

The bid quantity shall be fixed in following

manner- L-1(Single Bidder)100%

Between L-1 and Rate Matched Firm-1in the ratio of 60:40

Among L-1, Rate Matched Firm-1 and 2in the ratio of 50:25:25

The supply orders for quantity fixed as above may be issued as and when required. RMSCL has full rights to increase or decrease the bid quantity upto any limit during the contract period.

27. GRIEVANCE REDRESSAL DURING PROCUREMENT PROCESS:

The Designation and address of the First Appellate Authority is Mission Director, National Health Mission, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Additional Chief Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

(i) Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

- (ii) The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.
- (iii) If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

(iv) Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of procurement;
- (b) Provision limiting participation of Bidders in the Bid process
- (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a procurement process;
- (e) Applicability of the provisions of confidentiality.

(v) Form of Appeal (Annexure-X)

- (a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.
- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorized representative.

(vi) Fee for filling appeal

- (a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.
- (b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

(vii) Procedure for disposal of appeal

- (a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.
- (b) On the date fixed for hearing, the First Appellate Authority or Second Appellate Authority, as the case may be, shall,-
- (i) Hear all the parties to appeal present before him; and
- (ii)Peruse or inspect documents, relevant records or copies thereof relating to the matter.
- (c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.
- (d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

28. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:</u>

Any person participating in a procurement process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c) Not indulge in any collusion, Bid rigging or any-competitive behavior to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

- A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.
- I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:
 - a. Have controlling partners/shareholders in common; or
 - b. Receive or have received any direct or indirect subsidy from any of them; or
 - c. Have the same legal representative for purposes of the Bid; or
 - d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
 - e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or
 - f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
 - g. Bidder or any of its affiliates has been hired (or is proposed to be hired) by the Procuring Entity as engineer in-charge/ consultant for the contract.

29. FALL CLAUSE

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes / reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be automatically reduced with effect from the date of reducing or quoting lower price, for all delivery of the subject matter of procurement under that rate contract and the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving those fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

30. APPLICABILITY OF RULES

Besides above conditions the provisions of RTPP Act 2012 & RTPP Rule 2013 and Medical Devices Rules 2017 will be applicable.

Managing Director
Rajasthan Medical Services Corporation

RajKaj Ref 8172015

Total fee payable ? Commission ? Commission ? Total amount ?	
#	AUTION: USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM" Branch lustitute Name Rajasthan Medical Services Corporation, Jaipur RMSCJ-A/c No. 60460919022 DETAILS OF THE SUPPLIER Supplier Name Tender Ref. No. Solect any one out of "l'ends: Fees/EMD/SD/Tender Processing Mobile No. Cush Deposit: Chemie Demosit: Chemie Demosit: Chemie Demosit:
Cash Deposit: Cheque Deposit: Cheque Deposi	Branch Institute Name Institute ID Institute

Form A

(Apply in Duplicate) Application by MSME for price preference or Purchase Preference Or both in Procurement of Goods

Γο,	
The General Manager	
DIC, District	

- 1. Name of Applicant with Post
- 2. Permanent Address
- 3. Contact Details
 - a) Telephone No.:
 - b) Mobile no.:
 - c) Fax no.:
 - d) Email address:
- 4. Name of micro & small enterprise:
- 5. Office Address:
- 6. Address of Work Place:
- 7. No. & Date of Entrepreneurs Memorandum-II/Udyog Aadhaar Memorandum (enclose photo copy)
- 8. Products for which Entrepreneurs Memorandum-II/ Udyog Aadhaar Memorandum availed:
- 9. Products for which are at present being produced by the enterprise:
- 10. Products for which price preference or Purchase preference or both has been applied for:
- 11. Production capacity as per Capacity Assessment Certificate (enclose photocopy of Capacity Assessment Certificate)

Serial	Product	Production Capacity		
No		Quantity	Value	
1				
2				
3				
4				

12. List of Plant & Machinery installed

	Serial No	Name of Plant & Machinery	Quantity	Value
Ì	1			
	2			
	3			

RajKaj Ref 8172015 13. List of Testing Equipments installed

Serial No	Name of Plant & Machinery	Quantity	Value
1			
2			
3			
4			

- 14. Benefits availed as per price preference certificate in last financial year and current financial year
 - a. Benefits depositing Bid Security and Performance Security:

Last financial y	ear		Current financial year	
Departments	Bid	Performance	Bid	Performance
	Security	Security	Security	Security
	_		_	

b. Details of Supply orders received:

Last financial y	ear			Current financial year		
Departments	No. & Date of purchase order	Amount for which purchase order received	Amount of goods supplied	No. & Date of purchase order	Amount for which purchase order received	Amount of goods supplied

I declare that the above all facts given in the application are correct and my enterprise is producing the item (s) mentioned in column No. 10

Date	Signature
	(Name of the applicant
	along with seal of post)

CERTIFICATE

(See clause 3(ii))

File no			
Date)		
It is certified	that M/s		was inspected by
		on dated	
applicant. The	ntioned by the enterprise e enterprise is eligible for is notification. The certification	are correct as per the r r Price Preference or Pu	record shown by the irchase Preference or
Office Seal		Signatu (Full Name General M District Industi Rubber Seal	of the Officer) Ianager ries Centre
Enclosure-	(1) Application(2)(3)		

Format of Affidavit (On Non Judicial Stamp Paper of Rs. 10/-)

I
(b)My/Our above noted acknowledgement of Entrepreneurial Memorandum Part-II has not been cancelled or withdrawn by the Industries Department and that the enterprise is regularly manufacturing the above item (s). (c) My/Our enterprise is having all the requisite plant and machinery and is fully equipped to manufacture the above noted item (s).
Place Signature of Proprietor/Director Authorized Signatory with Rubber Stamp and date
VERIFICATION
I

DEPONENT

RajKaj Ref 8172015

ANNUAL TURN OVER STATEMENT

The	Annual Turnover	(for drugs and	l medicines i	ncluding	Surgical a	nd sutures
Business	or	medical	device		business)	of
M/s			for the	e past tl	hree years	are given
below and ce	ertified that the stat	ement is true and	d correct.	-		_

S.No.	Years	Turnov	ver in Crore (Rs)
1	2019-20		
2	2020-21		
3	2021-22		
Total		Rs.	Crore
Avera	ge turnover per annual	Rs.	Crore

<u>OR</u>

S.No.	Years	Turno	ver in Crore (Rs)
1	2020-21		
2	2021-22		
3	2022-23		
	Total	Rs.	Crore
Averaş	ge turnover per annual	Rs.	Crore

Date:	Signature of Auditor/
Seal:	Chartered Accountant (Name in Capital)
(Name in Capital)	•

UDIN:

AGREEMENT

			HORL	DIVILI V	1		
This	Deed of A	greement	is made or	ı this			day
of			2024 by	M/s		r	epresented by its
Proprie	ctor/Managing	g partner/M	Ianaging Di	rector	having	its Regist	ered Office at
					and	its Factor	y Premises at
						(hereinafte	er referred to as
							rs, executors and
							Medical Services
							wasthya Bhawan,
	•						which term shall
			tives, executo	rs assig	gns and ac	dministrator u	nless excluded by
the Co	ntract) on the					-	
. ~			-		y to the	Purchaser, t	he Item (s) with
specific			entioned below		_		••
			<u>y Counter Co</u>				
S.	Code No.		approved iter		Size	Packing	Approved
No.		(s) (S) wit	h specification	n		Unit	rate per
1	2		3		4	5	packing unit
				1 1			
og t1	in the mann he Supplie		r the terms an deposited	with	the	e in after mer Purchaser	ntioned and where a sum of
as th	ne Suppne	i iias	deposited	WILII	tile	Rup	
	nanca Sacurit	y for the du	and faithful	perform	mance of		ees only) as ent, to be forfeited
							ow these presents
							the Supplier and
							of them with the
			owing, that is t			ara agree eacr	1 01 1110111 111011 1110
1.			•		s connect	ion, shall mea	an and include the
							the Rate Contract
							(Two year Rate
	Contract en	ding on 30.	09.2026) (NI	B No	: F.02 (17	5)/RMSCL/Pro	oc./S&S (MD)/NIB-
	12/2024/3642	Dated:-19	.06.2024 and	techni	ical bid	opened on	12.07.2024), the
	instruction 1	to Bidders,	the condition	ns of	Bidder, a	acceptance of	f Bid, particulars
	hereinafter d	lefined and t	those general	and spe	ecial cond	ditions that m	ay be added from
	time to time.						
2.							e Supplier to the
						ted against ea	ach therein on the
			forth in the A				
	, ,	-					ith effect from the
							it shall remain in
	_		_	_			extended up to 3
						without any	y prior consent.
()			to accept the			1.1 1	11 / 11 /
(c)							d hereto indicates
	only the pro	bable total r	equirements of	of the F	urchaser	in respect of	each item for the

RajKaj Ref 8172015

Agreement Period indicated in Clause (b) above. This quantity may increase or decrease at the discretion of the Purchaser. The Supplier shall make supplies of the

surgical on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

- 1. (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as Performance Security and cancel the Contract.
 - (b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract. (c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.
- 2. The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3. All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, biding or be of any effect whatsoever.

SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4. The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Supplier permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SUPPLIER

5. In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SUPPLIER

- 6. All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.
- 7. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and bidding.
- 8. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decided by the Govt. and the decision of the Govt. shall be final.

SUPPLIER (Signature, Name EXECUTIVE DIRECTOR (P), & Address With Stamp) RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

Check List

Section	Details of requirement	Document Type	Yes/No If Yes Page No.
A	Mandatory documents	Challan/DD/ BC/NEFT/RTGS/IMPS generated receipt of Bid Security Deposit, Tender fee and RISL fee.	
		Manufacturing License (as per point 2 (b) of eligibility criteria)	
		Import License, if imported. ((as per point 2 (c) of eligibility criteria)	
		Sale License, in the case of imported item (s) ((as per point 2 (c) of eligibility criteria)	
		Non Conviction Certificate ((as per point 2 (d) of eligibility criteria)	
		Market Standing Certificate for manufacturer (as per 2 (e)) of eligibility criteria)	
		Quality Certificates (as per point 2 (e) of eligibility criteria)	
		Annexure-VII Declaration and Undertaking (as per 2 (h) of eligibility criteria)	
		The instruments such as power of attorney resolution of board etc	
В	Other Documents	Annexure-III -Annual Turnover Statement (as per 2 (h) of eligibility criteria)	
		GST registration and GST Return (as per 2 (i) of eligibility criteria)	
		Annexure-VI Check List Of Details Regarding Products Quoted	
		Documentary evidence for the constitution of the company / concern	
		Copies of balance sheet & profit loss account for three years	
		Copy of PAN Annexure-XI Undertaking For Empanelment	
		Annexure -XV Land Border Country Registration Requirement	
		Annexure –XVI Performance Security Declaration Annexure –XVII – No Deviation declaration	
		Documents for proof of experience 2 (g)	

Note:-In case of non submission of above mentioned mandatory documents with the original bid, the firm will be treated as Non-responsive and further question / queries / clarifications will not be sought.

Annexure - VI

(Ref. Clause : 2(c), 5(y)) Check list of details regarding products quoted Product permission and Marketing Standing as per condition 5 (i)(j)(v)

Sr · No ·	Quote d Item / Code no.	Product permissio n enclosed on page	Date of product permissio n	Generi c/ Brande d name of item	Specificatio n/ Compliance as per code No.	Catalog ue Number/ Product IFU	Name of agency for quality certification eg. WHO-GMP/COP P/USFDA etc	proo Mk	per M duct M d sinco 3 year	Ifg & e last
		no.	Approval		Yes/ No			Pag e No.	Yes / No	Dat e of Issu e
1										
2										
3										
4										
5										

Declaration & Undertaking Ref. No.: F.02 (175)/RMSCL/Proc./S&S (MD)/NIB-12/2024/ Dated:(On Non-Judicial Stamp Paper of Rs 500/- Self Attested)

I Name	e S/o	o		Age	Prop./Partne	er/Director/	/Authorize	ed
Person/	Power of attorney	holder of	firm	M/s	S	ituated at	(Comple	te
address	of Mfg. unit)						_	
	bearing 1	medical	devic	e licens	se numl	oer iss	ued o	on
dated	valid/R	enewed up	to		do here b	by declare	on oath a	as
follows:	=	_						

- 1. That none of the quoted Surgical manufactured by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
- 2. That the quoted product is manufactured/imported by us, and none has been declared as "Not of standard quality" during last two years.

3. That we have following Commitment of quantity in our plant at above address:-[Ref. Clause No. 11(2) & 25 (i)]

S. N o.	Quoted item Code No. & Name of surgical	Monthly Capacity in all shifts in nos.	Annual Productio n Capacity	Supply Commitment quantity during rate contract period(not be less than estimated bid	Estimated Bid Quantity as per Annexure VIII	GSTIN Number & Name of state where GSTIN registered
				estimated bid quantity)		
1.						
2.						

Bidder is bound to supply minimum 5% of bid quantity on monthly basis and entire bid quantity within the contract period as per purchase order.

- 5. That our Firm/Company and its Proprietor/Partner/Directors/ Power of attorney holders have not been convicted for contravention of any provisions of Drugs & Cosmetic Act 1940 and rules made there under since grant of license. I have not been

- convicted under the Prevention of Corruption Act; or under the Indian Penal Code 1860 or any, other law for the time being in force, for causing any loss of life or property, or causing a threat to public health as part of execution of a public procurement contract.
- 6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

S.No	Code	Name	Date of	Trade/Brand	Issuing	Own	Sale	Manufacturi
			product		Licensin	manufacturin	Licensin	ng /import
		product	permissio	(Please	g	g/ Direct	g	number for
			n		authority	Importer	number	quoted item
			obtained				(in case	
			from the				of	
			licensing				importer	
			authority				item(s)	
1			•				, ,	
2								

- 7. That we have over three years experience in the manufacture of the quoted product or the quoted imported product has over 3 years market standing.
- 8. That we have own in-house testing laboratory wherein all the tests required w.r.t. the quoted products are carried out.

- 11. That I will supply the Surgicals /Sutures per the designs given in Bid clause no 15 and as per the instructions given in this regard.
- 12. That I/We have carefully read all the conditions of Bid in Ref. no. Ref. No.: F.02 (175)/RMSCL/Proc./S&S (MD)/NIB-12/2024/3642 Dated:-19.06.2024 for E-Bid for supply Cum rate contract of Surgical (Two year Rate Contract ending on 30.09.2026) for Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if any If case of typographical error found in submitted documents / affidavits, in this case we accept all the Terms and conditions of bid documents.
- 13. I/We agree that the Bid Inviting Authority forfeiting the Bid security and or Performance security and blacklisting/Debarring/Banning me/ us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Medical Device Rules 2017 of the said Act or at any time during the Bid process.

- 14. I/ we hereby declare under Section 7 & 11 of Rajasthan Transparency in Public Procurement Act, 2012 that:
 - a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I / we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my / our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.
 - f. We have complied and shall continue to comply with the Code of Integrity as specified in the Rajasthan Transparency in Public Procurement Act, the Rajasthan Transparency in Public Procurement Rules and this Bidding Document, till completion of all our obligations under the Contract.
- 15. The quoted rates of any item (s) is not more than the price fixed by the govt. under the current drugs (Price control) order.
- 16. I/We undertake that I/We shall strictly adhere to the provisions of clause number 29 "Fall clause" of Bid document.
- 17. The submitted Average Annual Turnover certificate is related to (for drugs and medicines including Surgical and sutures Business or medical device business).

<i>18</i> .	Our complete address for communication
	Pin
	E-mail address : -
	Phone No. /Mobile No.
	PAN of the firm
19 .	Bank detail for e banking :-
	Name of account holder
	Full name of Bank with Branch
	A/c no. with full digits
	IFSC code

(Name of Deponent & Signature)
(Designation)

Verification

(Name of Deponent & Signature)

Witness: - (Name, Address & Signature)

1

2

* Certificates on which validity period has not been mentioned, then issue date of such certificate should not be older than one year from the last date of submission of application/bid.

	Annexure –VIII (Ref. Clause- 5(a) 9c), 11(2,3)) <u>List of Item (s) with Specifications</u>										
S. No	Item code	Drug Name	Shelf Life (In months)	Packin g unit	Quantity	Estimated Cost with GST	Bid Security 2% of Estimated Cost				
1	NES- 15	 HIV (ELISA) testing kits IV generation. Should be solid phase micro plate coated HIV I & II recombinant and/or synthetic peptide antigens and antibody to HIV 1 p24. The assay should detect HIV 1 and II antibodies and HIV 1p24 antigen. Micro wells coated with a mixture of recombinant HIV antigens gp120, gp41 and gp36 & monoclonal antibodies to HIV p24 antigen. Analytical sensitivity of p24 Ag should not be less than 20 pg/ml. Adequate documents detailing the principle, components, details of antigen for antibody, detection of HIV 1 and 2 Antigen, biosafety, methodologies validity, criteria interpretation of results, performance characteristics, storage conditions, limitation of assays manufacturing, & expiry dates should be provided with each kit. The kit should have approval of the statutory authority in its country of origin. In case of imported kits it should be registered and licensed under the provisions of Drugs & cosmetics Act and rules/ or Medical devices rules 2017 in India. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics, Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and Cosmetics Act, 1940, The kit should have minimum remaining shelf- life of 5/6" or 12 months {Whichever is more) the port of discharge of consignees, The assay component should include reactive (for both antibody as well as antigen) and non- reactive controls with each kit. The assay should have sensitivity level of 100% and specificity level of more than or equal to 99%. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. The temperature indicator should be placed on every pack of kit. The pack size should be 96 tests/kit. 	12	Pack size should be 96 tests/ kit. But rate should be coated each test	400000	5740000	114800				
2	NES-	Hepatitis B Surface Antigen (Elisa) Testing	817201 12	kit size	400000	6296000	125920				

1. An ELISA reader based qualitative test 2. Should have polyclonal antibodies coated on the solid, phase & monoclonal antibodies in the conjugate to detect all subtypes & mutant strains. The assay should be able to detect surface antigen to hepatitis by triss. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, bio-safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 56° or 21 months (whichever is more) at the port of discharge of consignees. 9. The assay should have sensitivity of 100% and specificity of more than or equal to 50pg/ml. 10. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c × 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.		1.7			ala a sal al			
2. Should have polyclonal antibodies coated on the solid, phase & monoclonal antibodies in the conjugate to detect all subtynes & mutant strains. The assay should be able to detect surface antigen to hepatitis b virus. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, biosafety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017; suced by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5x6° for 12 months (whitehever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits.		17	Kits IV Generation/High sensitive		should			
on the solid phase & monoclonal antibodies in the conjugate to detect all subtypes & mutant strains. The assay should be able to detect surface antigen to hepatitis by trues. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, bio-safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be cliensed under the provisions of Drugs & Cosmetics act and rules and or medical devices rules 2017 in medical devices rules 2017 in the dia, 8. The kit should have minimum shelf- life of 56% or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay should have sensitivity of 100% and specificity of more than or equal to 509/6. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 509/6. 11. The assay should have resitivity of 100% and specificity of more than or equal to 509/6. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2% c. 8% C. Temperature indicator to be placed on every box of kits.			1. An ELISA reader based qualitative test					
on the solid, phase & monoclonal antibodies in the conjugate to detect all subtypes & mutant strains. The assay should be able to detect surface antigen to hepatitis B virus. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, biosafety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and/or medical devices rules 2017 is used by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 56% or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have analytical sensitivity of detecting less than or equal to 590g. 11. The assay should have analytical sensitivity of detecting less than or equal to 590g. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits.			2. Should have polyclonal antibodies coated		tests/ki			
antibodies in the conjugate to detect all subtypes & mutant strains. The assay should be able to detect surface antigen to heparitis B virus. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, bio-safety methodologies, validity critera, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 55% or 12 months (whichever is more) at the port of discharge of consigness. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99%. 11. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			on the solid phase & monoclonal		t. But			
subtypes & mutant strains. The assay should be able to detect surface antigen to hepatitis B virus. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, bio- safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory suthority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 ^{roi} or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay sound have ensitivity of 100% and specificity of more than or equal to 99%. 11. The assay should have ensitivity of 100% and specificity of more than or equal to 599mill. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2 ^{roc} - 8 ^{roc} . Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.					rate			
should be able to detect surface antigen to hepatitis B virus. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, bio- safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmeties act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6" or 12 months (whichever is more) at the port of discharge of consigness. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 509g/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2"c - 8"C. I remperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.					should			
nepatitis B virus. 3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, biosafety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5% th or 12 months (whichever is more) at the port of discharge of consigness. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 509g/ml. 11. The assay should have analytical sensitivity of detecting less than or equal to 509g/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			1		be			
3. Total incubation time should not be more than 90 minutes. 4. Adequate documents detailing the principle components, bio- safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 56% or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.					coated			
than 90 minutes. 4. Adequate documents detailing the principle components, bio-safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutuory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6° or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
4. Adequate documents detailing the principle components, bio- safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmeties act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 556 or 12 months (whichever is more) at the port of discharge of consigences. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99%. 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C, Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
principle components, bio safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6% or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99%. 11. The assay should have sensitivity of 100% and specificity of more than or equal to 50/g/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.					test			
methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6% or 12 months (whichever is more) at the port of discharge of consigences. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have sensitivity of 100% and specificity of more than or equal to 50pg/ml. 12. All the reagents should have analytical sensitivity of detecting less than or equal to 50pg/ml. 13. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			1					
interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 516" or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2"e - 8"C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have sensitivity of 100% and specificity of more than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6/6 or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 90% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay compent should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 999% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			limitation of assays manufacturing &					
5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			expiry dates should be provides with each					
statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 to 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2 to 2 - 8 °C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			kit.					
statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 to 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2 to 2 - 8 °C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			5. The kit should have approval of the					
6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 its usued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/h or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
rules and/or medical devices rules 2017 in India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
India, 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/ or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			1					
7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the compectent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6¹¹¹ or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/h or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non-reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			·					
8. The kit should have minimum shelf- life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
of 5/6 th or 12 months (whichever is more) at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 999% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
at the port of discharge of consignees. 9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
9. The assay component should include reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
reactive and non- reactive controls. 10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
10. The assay should have sensitivity of 100% and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
and specificity of more than or equal to 99% 11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.								
11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit.			1					
11. The assay should have analytical sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015			99%					
sensitivity of detecting less than or equal to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015			11. The assay should have analytical					
to 50pg/ml. 12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
12. All the reagents should in ready to use form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
form. Only wash buffer concentrate to be reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
reconstituted before use. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
maintenance of cold chain during storage & transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
& transport the kits at 2°c - 8°C. Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
Temperature indicator to be placed on every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
every box of kits. 13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
13. The kit size should be 96 tests/kit. RajKaj Ref 8172015								
RajKaj Ref 8172015								
8172015			13. THE KIT SIZE SHOULD DE 90 TESTS/KIT.					
8172015								
8172015								
8172015								
8172015								
8172015								
8172015								
2 NEC 101 400000 22100000 (C2C00			F	RajKaj Ro	ef			
5 NES- HCV (Elisa) Testing Kits IV Generation 12 pack 400000 33180000 663600		NIEG		817201		400000	22100000	((2(00
	_ 3	NES-	HCV (Elisa) Testing Kits IV Generation	12	pack	400000	33180000	663600

	18	 Microplate ELISA coated with recombinant/ synthetic peptide antigens for core. NS3 NS4 and NSS and antibody to HCV core Antigen. Should be based on Indirect Assay for Antibody detection & Sandwich for Antigen detection. Total Incubation time should not be more than 150 minutes. Positive & negative controls for antigen & antibody should be ready to use. Adequate documents detailing the principle, components, bio- safety methodologies validity criteria, interpretation of results, performance characteristics, storage conditions, limitation of assays manufacturing & expiry dates should be provided with each kit. The kit to be procured should have approval of the statutory authority in its country of origin. In case of imported kits it should be registered and licensed under the provisions of Drugs cosmetics Act and rules and/or medical devices rules 2017 in India. In case of indigenous manufacturers should be licensed under the provisions of Drugs &cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act 1940. The kit should have minimum shelf-life of 5/6thor 12 months (whichever is more) at the port of discharge of consignees. The assay component should include reactive (for both antibody and antigen) and non-reactive controls. The assay should have a sensitivity of 100% and specificity of more than or equal to 98%. The manufacturer should ensure maintenance of cold chain during storage & transport the kits at 2°c - 8°c. The time temperature indicator should be placed on every pack of kits. The pack size should be 96 tests/kit. 	size should be 96 tests/ki t But rate should be coated each test			
4	NES- 19	 HIV (Rapid) testing kits Test should be a solid coated HIV 1 & HIV II recombinant and/or synthetic peptide antigens. The assay/test assay should detect total antibodies (lgG, lgM & lgA) specific to HIV-1 & HIV-2 in human serum, plasma & whole blood. The assay should utilize recombinant HIV-1 capture antigens i.e. gp41 and gp120) for 	12 pack size should not be more than 50 tests/ki 8172015 rate should	300000	3429000	68580

detection of HIV 1 antibodies & be recombinant HIV-2 capture antigen i.e. gp36 detection of HIV 2 antibodies. 4. Adequate documents detailing the principle, components, details of antigen for antibody detection of HIV 1 and 2, bio-safety methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics and the provisions of drugs & cosmetics and or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics and rules and or medical devices rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6° or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immumolpholulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 16. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg. 2. The assay should be able to detect util 11 sub types of HBsAg. 2. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect					1			
gp36 detection of HIV 2 antibodies. 4. Adequate documents detailing the principle, components, details of antigen for antibody detection of HIV 1 and 2, bio-safety methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf: life of 5/6° or 12 months (whichever is more) at the port of discharge of consignees. 9. The tinsould have minimum shelf: life of 5/6° or 12 months (whichever is more) at the port of discharge of consignees. 9. The tinsould have minimum shelf to the detect the presence of human immunoglobulin and should he able to detect the presence of human immunoglobulin and should hot be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 NES- 20 Hepatitis B surface antigen (Rapid) testing. kits 1. Should be solid phase/ particle coated with monoclonal antibodies to Hiskag 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of Hiskag. 4. The speak point will fine the combination of the storage of the sto			detection of HIV 1 antibodies &		be			
4. Adequate documents detailing the principle, components, details of antigen for antibody detection of HIV 1 and 2, bio- safety methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmeties act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices rules and or medical devices. 9. The time required of performing the test should not be more with documentary evidence. 10. The control dot/ band should be packed such that there is a provision to conduct single test at a time. 11. The pack size should not be more than 50 tests/kits. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size sho			recombinant HIV-2 capture antigen i.e.		coated			
components, details of antigen for antibody detection of HIV I and 2, bios safety methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmeties act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmeties act post of			gp36 detection of HIV 2 antibodies.		each			
detection of HIV 1 and 2, bio- safety methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of \$66* or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrily of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 15. NES- 20 16. Hepatitis B surface antigen (Rapid) testing kits 17. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The serva pland kutifica the combination of the state that the control of the contr			4. Adequate documents detailing the principle,		test			
detection of HIV 1 and 2, bio- safety methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmeties act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmeties act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmeties act, 1940. 8. The kit should have minimum shelf-life of 5/6°or 12 months (whichever is more) at the port of discharge of consigness. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot) band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 15. NES-20 16. Hepatitis B surface antigen (Rapid) testing kits 17. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The storage able to detect all 11 sub types of HBsAg. 4. The storage able to detect all 11 sub types of HBsAg.								
methodologies validity criteria interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 55/6/0 rol 2 months (whichever is more) at the port of discharge of consigness. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the anigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 Hepatitis B surface antigen.(Rapid) testing. kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg 2. The assay should be able to detect all 11 sub types of HBsAg 3. The assay should be able to detect all 11 sub types of HBsAg 4. The storage change of the storage antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg								
interpretation of results performance characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf: life of 5/6**or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays. 11. The assay should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30*C. 5 NES-20 15. NES-20 16. NES-20 17. The stars and the select surface antigen to Hepatitis B virus. 18. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg. 20. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The pack size should not be more than 50 tests/kits. 18. The stars any should be able to detect surface antigen to Hepatitis B virus. 3. The pack size should not be more than 50 tests/kits. 19. The saxes yshould be able to detect all 11 sub types of HBsAg. 20. The saxes yshould be able to detect all 11 sub types of HBsAg.								
characteristics storage conditions limitation of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 56/6 or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 15. NES-30 16. The saxs should be able to detect all 11 sub types of HBsAg. 26. The saxs should be able to detect all 11 sub types of HBsAg. 27. The saxs should be able to detect all 11 sub types of HBsAg. 28. The saxe whould validize the combination of tests sub types of HBsAg.								
of assays manufacturing & expiry dates should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/b° of 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays. 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 15 NES-20 16 Hepatitis B surface antigen (Rapid) testing kits. 1 Should be solid phase/ particle coated with monoclonal antibodies to HBsAg. 2 The saxsy should be able to detect surface antigen to Hepatitis B virus. 3 The cassay should be able to detect surface antigen to Hepatitis B virus. 3 The saxsy should be able to detect all 11 sub types of HBsAg. 4 The saxe whould virilize the combination of the tests and the state of the state o								
should be provided with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act 1940. 8. The kit should have minimum shelf- life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays. 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test it should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg. 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The acream chould tailize the combination of the state								
5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmeties act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmeties act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/"or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect all 11 sub types of HBsAg. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The argus should table to detect all 11 sub types of HBsAg. 50 the argus should be able to detect all 11 sub types of HBsAg. 51 The argus should be able to detect all 11 sub types of HBsAg. 52 The argus should be able to detect all 11 sub types of HBsAg. 53 The argus should be able to detect all 11 sub types of HBsAg.								
statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and-cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/0 rol 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect all 11 sub types of HBsAg. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The areas chould tail/ize the combination of the state of the state of the state antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The areas chould tail/ize the combination of the state of the s								
6. In case of imported kits if should be registered and licensed under the provisions of drugs & cosmetics act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 hor 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 Kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect all 11 sub types of HBsAg. 3. The gasay should be able to detect all 11 sub types of HBsAg. 4. The argus chould tailize the combination of the sub tests and the sub tests and the sub tests tests.			**					
registered and licensed under the provisions of drugs & cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and-cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6lbr 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 Hepatitis B surface antigen (Rapid) testing. kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect all 11 sub types of HBsAg. 3. The sassy should be able to detect all 11 sub types of HBsAg. 4. The starsy chould tailing the combination of								
provisions of drugs & cosmetics act and rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and- cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6*0r 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 15 NES-20 16 NES-20 17 NES-30 The assay should be able to detect surface antigen to Hepatitis B virus. 28 The assay should be able to detect all 11 sub types of HBsAg. 29 The assay should be able to detect all 11 sub types of HBsAg. 40 The assay should tilize the combination of the surface antigen to Hepatitis B virus. 30 The assay should be able to detect all 11 sub types of HBsAg. 41 The assay should the able to detect all 11 sub types of HBsAg. 42 The assay should this at the combination of the surface antigen to Hepatitis B virus.								
rules and/ or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6/°or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 15 NES-20 16 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The steray chould tilize the combination of								
India. 7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6*bro 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 15 NES-20 16 Hepatitis B surface antigen (Rapid) testing kits 1 Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2 The assay should be able to detect surface antigen to Hepatitis B virus. 3 The pack size should be able to detect surface antigen to Hepatitis B virus. 3 The pack of HBsAg. 4 The assay should be able to detect all 11 sub types of HBsAg. 4 The assay should be able to detect all 11 sub types of HBsAg. 5 But			provisions of drugs & cosmetics act and					
7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen the pattern of the size should not be more than 50 tests/kits. 3. The assay should be able to detect surface antigen the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the pattern of the size should not be more than 50 tests of the size should not be more than 50 tests of the size should n			rules and/ or medical devices rules 2017 in					
should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6% or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen the Hepatitis B virus. 3. The passay should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of the serget should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of the serget should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of the serget should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of th			India.					
should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6% or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen the Hepatitis B virus. 3. The passay should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of the serget should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of the serget should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of the serget should be able to detect all 11 sub types of HBsAg. 4. The serget kendy triling the combination of the serget should triling the combination of th			7. In case of indigenous manufacturers					
drugs & cosmetics act and rules and or medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6"or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg. 2. The assay should be able to detect all 11 sub types of HBsAg. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should will/are the combination of tests.								
medical devices Rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6 the 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 Kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg. 2. The assay should be able to detect all 11 sub types of HBsAg. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should wilkizs the combination of the sub types of HBsAg. 4. The assay should wilkizs the combination of the sub types of HBsAg.								
competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf-life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should the application of feet and the properties of the state and								
and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6/16/12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. NES- Hepatitis B surface antigen (Rapid) testing 12 pack size should not be more than 50 tests/kits. 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should the combination of tests But Should Sho								
8. The kit should have minimum shelf- life of 5/6/hor 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES- 20 **Repatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect all 11 sub types of HBsAg. 5. The assay should be able to detect all 11 sub types of HBsAg. 6. The assay should be able to detect all 11 sub types of HBsAg. 7. The assay should be able to detect all 11 sub types of HBsAg. 8. The assay should be able to detect all 11 sub types of HBsAg. 9. The assay should be able to detect all 11 sub types of HBsAg. 1. The assay should be able to detect all 11 sub types of HBsAg.								
of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. S NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should the combination of								
at the port of discharge of consignees. 9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. NES- 20 NES- 20 NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should the combination of								
9. The time required of performing the test should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. 5 NES-20 NES-20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be combination of								
should not be more than 20 minutes. 10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. NES-20 Hepatitis B surface antigen (Rapid) testing kits 12 pack size should not be more than 50 tests/kits. 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should be able to detect all 11 sub types of HBsAg.								
10. The control dot/ band should be able to detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Description								
detect the presence of human immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should tillize the combination of the tests are the combination of the tests are then the combination of tests and the								
immunoglobulin and should not be just a "procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. The string of the particle coated with monoclonal antibodies to HBsAg Size should not be more than 50 tests/kits Should be solid phase/ particle coated with monoclonal antibodies to HBsAg The assay should be able to detect surface antigen to Hepatitis B virus. The assay should tillize the combination of tests But t								
"procedural control" or meant for merely checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits Should be solid phase/ particle coated with monoclonal antibodies to HBsAg The assay should be able to detect surface antigen to Hepatitis B virus. The assay should be able to detect all 11 sub types of HBsAg. But The assay should utilize the combination of the state of the								
checking the flow of reagents or integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits Should be solid phase/ particle coated with monoclonal antibodies to HBsAg The assay should be able to detect surface antigen to Hepatitis B virus. The assay should be able to detect all 11 sub types of HBsAg. The assay should trilize the combination of the state of the sta								
integrity of the antigen. Except for lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits Should be solid phase/ particle coated with monoclonal antibodies to HBsAg The assay should be able to detect surface antigen to Hepatitis B virus. A The assay should be able to detect all 11 sub types of HBsAg. The assay should be able to detect all 11 sub types of HBsAg. A The assay should tilize the combination of the state of								
lateral flow assays 11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of the state of th			checking the flow of reagents or					
11. The assay should have sensitivity of 100% and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should willig the combination of the substance of the says and the same time to the says and the same time than the says and the same time than the same time time time than the same time time time time time time time ti			integrity of the antigen. Except for					
and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. NES-20 Hepatitis B surface antigen (Rapid) testing kits 12 pack size should not be monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of the subtypes of HBsAg. 4. The assay should utilize the combination of the subtypes of HBsAg. 4. The assay should utilize the combination of the subtypes of HBsAg. 300000 packed such that there is a provision to conduct single test at a time. 12 pack size should not be more than 12 pack size should not be more than 12 pack packed size should provided that there is a provision to conduct single test at a time. 12 pack size should not be more than 12 pack size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be packed size size should not be packed size size size size should not be packed siz			lateral flow assays					
and specificity of 99 % or more with documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. NES-20 Hepatitis B surface antigen (Rapid) testing kits 12 pack size should not be monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of the subtypes of HBsAg. 4. The assay should utilize the combination of the subtypes of HBsAg. 4. The assay should utilize the combination of the subtypes of HBsAg. 300000 packed such that there is a provision to conduct single test at a time. 12 pack size should not be more than 12 pack size should not be more than 12 pack packed size should provided that there is a provision to conduct single test at a time. 12 pack size should not be more than 12 pack size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be more than 12 pack packed size should not be packed size size should not be packed size size size size should not be packed siz			11. The assay should have sensitivity of 100%					
documentary evidence. 12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. MES-20 Hepatitis B surface antigen (Rapid) testing kits 12 pack size should not be monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of the state of								
12. The test kit should be packed such that there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of			1 2					
there is a provision to conduct single test at a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits Should be solid phase/ particle coated with monoclonal antibodies to HBsAg The assay should be able to detect surface antigen to Hepatitis B virus. The assay should be able to detect all 11 sub types of HBsAg. The assay should wilities the combination of tests at the combination of tests are the combination of tests at the combination of the combination of tests at the com								
a time. 13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Hepatitis B surface antigen (Rapid) testing kits Should be solid phase/ particle coated with monoclonal antibodies to HBsAg The assay should be able to detect surface antigen to Hepatitis B virus. The assay should utilize the combination of tests But								
13. The pack size should not be more than 50 tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Solution Hepatitis B surface antigen (Rapid) testing kits 12 pack size should 12 pack size should 12 pack size should 13 pack size should 14 pack size should 15 pack size should 16 pack size should 16 pack size should 17 pack size should 18 pa								
tests/kits. 14. The storage & transport temperature of the Kit should be 2-30°C. Should be 2-30°C. 12 pack size should 15 pack size should 16 pack size should 16 pack size should 16 pack size should 17 pack size should 18 pack size should 18 pack size should 19 pack size should 19 pack size should 10 pack size should								
14. The storage & transport temperature of the Kit should be 2-30°C. NES-20 Hepatitis B surface antigen (Rapid) testing 12 pack size should 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 3 But 3 00000 1701000 34020 34								
Kit should be 2-30°C. Solution Hepatitis B surface antigen (Rapid) testing 12 pack size should 12 size should 13 14 15 15 15 15 15 15 15								
5 NES- 20 Hepatitis B surface antigen (Rapid) testing kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of								
kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of			Kit Siloulu de 2-30 C.					
kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of								
kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of	5	NES-	Henatitis B surface antioen (Ranid) testing	12	pack	300000	1701000	34020
kits 1. Should be solid phase/ particle coated with monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of					-			
monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of					should			
monoclonal antibodies to HBsAg 2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of			1. Should be solid phase/ particle coated with		not be			
2. The assay should be able to detect surface antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of					more			
antigen to Hepatitis B virus. 3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of								
3. The assay should be able to detect all 11 sub types of HBsAg. 4. The assay should utilize the combination of states.								
sub types of HBsAg. 4. The assay should utilize the combination of								
1. The assay should utilize the combination of								
			1 The access chould utilize the combination of		4			
Monoclonal & polyclonal antibodies to polyclonal should			Monoclonal & polyclonal antibodies to		should			
UDa A a for detection Rajnaj Rei			HBsAg for detection	RajKaj R	ef ^{onound}			
8172015 be			TIDS/15 for detection.	817201	5 be _			
5. Adequate documents detailing the coated principle components, bio-safety			•		Coated			
principle components, old surety			principle components, 010- safety		<u> </u>			

		methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 6. The kit should have approval of the statutory authority in its country of origin. 7. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 8. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and. or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940, 9. The kit should have minimum shelf- life of 5/6th or 12 months (whichever is more) at the port of discharge of consignees. 10. The total procedure time shall not be more than 30 minutes. 11. Assay should have Sensitivity 100% & specificity 100% or more with documentary evidence. 12. The storage & transport temperature of the Kit should be 2-30°C. 13. The pack size should not be more than 50 tests wherein each test is individually packed.		each			
6	NES- 21	 HCV (Ragid) testing kits Should be solid phase/ particle coated with recombinant and / or synthetic peptide antigens for Core, NS3, NS4 and NSS. The assay should able to detect total antibodies (lgG, lgM & lgA) specific to HCV in human serum, plasma or whole blood. Adequate documents detailing the principle, components, bio- safety methodologies, validity criteria interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provided with each kit. The kit to be procured should have approval of the statutory authority in its country of origin. The kit should have approval of the statutory authority in its country of origin. In case of imported kits it should be registered and licensed under the provisions of drugs & cosmetics act and rules and/ or niedical devices rules 2017 in India. 	12 RajKaj Re 817201		300000	3429000	68580

	7. In case of indigenous manufacturers should be licensed under the provisions of drugs & cosmetics act and rules and or medical devices rules 2017 issued by the competent authority defined under drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life of 5/6" or 12 months (whichever is more) at the port of discharge of consignees. 9. The total procedure time shall not be more than 20 minutes. 10. Assay should have Sensitivity 100% & specificity 100% or more with documentary evidence 11. The storage & transport temperature of the Kit should be 2-30°C. 12. The pack size should not be more than 50 tests wherein each test is individually evidence.
7 NES- 22	SyphilisAntibody (Rapid) detection kits 1. The assay should be based on Rapid chromatographic immunoassay for qualitative detection of Antibodies (IgG, IgA & IgM) to TP in serum, plasma & whole Blood. 2. The assay should utilize recombinant Treponemal antigens i.e. Tp15, Tp17, Tp47 against Syphilis. 3. The assay should be in card format. 4. Adequate documents detailing the principle components, bio- safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry dates should be provides with each kit. 5. The kit should have approval of the statutory authority in its country of origin. 6. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 7. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 8. The kit should have minimum shelf- life

		of 5/6th or 12 months (whichever is more) at the port of discharge of consignees. 9. Read result time should not be more than 20 minutes. 10. Assay should have Sensitivity 100% & specificity 99 %or more with documentary evidence. 11. The storage & transport temperature of the Kit should be 2-30°C. 12. The pack size should not be more than 50 tests wherein each test is individually				
8	NES- 23	Malaria Antigen (Rapid) detection test 1. Test should be based on Immunochromatographic assay. 2. The test should able to differentially detects Antigen of P. falciparum (HRP-2/ LDH) and Pan Plasmodia against P. falciparum, P. vivax, P. ovale, P. malariae (LDH) from human whole blood.in two different brand/lines. 3. The test band & control band should have different colours/same colours for differentiation of control & Test band with respect to use of whole blood as a sample. 4. The membrane strip should be pre-coated with the antibodies specific to Histidine-rich protein II (HRP II) of P. falciparum on Pf test line and specific to the lactate Dehydrogenase (pLDH) Plasmodium species (P. falciparum, P. vivax, P. malariae, P. ovale) on Pan test line separately 5. The test should be in card format not in strip. 6. Adequate documents detailing the principle components, bio- safety methodologies, validity criteria, interpretation of results, performance characteristics storage conditions, limitation of assays manufacturing & expiry. dates should be provides with each kit. 7. The kit should have approval of the statutory authority in its country of origin. 8. In case of imported kits it should be registered and licensed under the provisions of Drugs & Cosmetics act and rules and/or medical devices rules 2017 in India. 9. In case of indigenous manufacturers should be licensed under the provisions of Drugs & cosmetics Act and rules and or medical devices rules 2017 issued by the competent authority defined under Drugs and cosmetics act, 1940. 10. The kit should have minimum shelf- life of 5/6th or 12 months (whichever is more) at the port of discharge of consignees. 11. Read result time should not be more than 30 minutes. 12. The storage & transport temperature of the kit should be 2-30°C.	12 RajKaj R 817201	800000	8688000	173760

13. The pack size should not be more than 50 tests wherein each test is individually packed.		
Total	68687000	1373740

RAJASTHAN MEDICAL SERVICES CORPORATION LTD GUIDELINES FOR BLACK LISTING / DEBARRING OF PRODUCT OR COMPANY

1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:

The tenderer who submits false, forged or fabricated documents or conceals facts with intent to win over the tender or procure purchase order; EMD of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.

2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:

2.1 The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, Bid Security Deposit of such Bidder firm shall be forfeited.

If an LoA for more than one products is issued to a successful bidder and he/she/it fails to execute agreement for few item (s), in such case, bid security of that item shall be forfeited and the product for which agreement is not executed shall be debarred for a period of not less than 3 years.

2.2 The successful Tenderer after entering into an agreement withdraw or fail to honour commitments as per tender conditions, Security Deposit of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years.

3. ON ACCOUNT OF NON-SUPPLY:

- 3.1 The supplier shall start to supply according to tender condition from the date of purchase order and shall complete the supplies within 60/75 days as mentioned in Purchase Order or as stated in tender condition.
- 3.2 RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the tender documents. In the event of acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the tender document.

- 3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.
- 3.4 If the supplier fails to execute atleast 50% of the quantity mentioned in single purchase order and such failure in supply continues for three purchase orders, then supplier firm will be liable for debarring for a period of 2 years. As a result such supplier will be ineligible to participate in any of the tenders for particular item(s) of drugs / medicines for a period of 2 years.

4. ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:

- 4.1 The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.
- **4.2** Samples of all sterile surgicals item (s) falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.
- **4.3** If such samples **pass** quality test in all respects, RMSC will instruct its Warehouses to issue item (s) of drugs to various hospitals / institutions
- **4.4** If the sample fails in quality test and report is received certifying that sample is **not of standard quality**, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the tender documents.

Minor defects

- 4.5 (1) If one batch of a particular item supplied during contract period fails in any of the quality test conducted by the tender inviting authority and/or by the Drugs Control Department, then Penalty of not less than 5.0% of Purchase Order value of that particular item shall be levied."
- 4.5 (2) If two batches of a particular item supplied during contract period fail in any of the quality tests conducted by the tender inviting authority and/or by the Drugs Control Department, then that particular product of that firm will be blacklisted for a period up to 3 years but not less than 06 months in any case.

- (*Tablets/Capsules failing in dissolution test and active contents found 70% and above for thermo labile products and upto 5% less than the prescribed limits for thermo stable products.) Grossly substandard
- **4.6** (1) If **any batch of a particular item** supplied under a tender tenure by the supplier is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab which falls in **grossly substandard** category and such failure is further confirmed by another empanelled lab / Govt. Lab, then the product shall be liable for debarring for a period of not Less than one (1) years.
- (2) If **two or more batches** supplied under a tender tenure by the supplier is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab, which falls in **grossly substandard** and such failure is further confirmed by Govt. Lab, then the **Product** shall be liable for debarring for a period of not less than two (2) years.
- **4.7** If the supplier supplied **more than one drug** (subject to a minimum of 6 drugs) during a tender duration and 50% of such drugs are blacklisted, the **firm** is liable to be blacklisted for a period of **2 vears** from the date of intimation after observing the procedure.

Spurious or Adulterated

- **4.8** In case, any sample (even one batch) is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab which falls in **Spurious or Adulterated** category and if such failure is further confirmed by Govt. Lab during its entire shelf life, the **Company** shall be liable for debarring for a period of **not less than 5 years**.
- **4.9** If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is challenged then the report of Director, C.D.L., Kolkata shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of debarring of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for debarring the product for not less than 2 years and in case of involvement of three different products the **Supplier / Company** as a whole shall be liable for debarring for a period of not Less than 3 years.

5 PROCEDURE IN THE EVENT OF QUALITY FAILURE WILL INVOLVE THE FOLLOWING STEPS:

- **5.1** On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.
- **5.2** Warehouse In-charge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.
- **5.3** Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the by QC Cell.
- **5.4** The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse In-charge will be directed to contact the District Drugs Control officer for drawing statutory sample of such batch as per Act. The DDW In-charge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.
- **5.5** In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in sub-Para 5.2 will be followed in respect of stock available with the warehouse. In respect of stock already issued and drug warehouse In-charge will take immediate steps to RETRIEVE the unused stock of such drugs from all such institutions and D.D.C.s by all possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.
- **5.6** On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.

5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.

5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC

6.1 Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.

6.2 The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Debarring of the particular product or supplier/company.

6.3 If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the tenders for the particular item floated by RMSC for the specified period. For such purpose period of debarring will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for participating in any of the tenders for any of the item (s) during blacklisted period.

7. POWER OF REVIEW:

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

8. RIGHT TO APPEAL:

Any supplier / company against whom the above action is taken may prefer an appeal within 30 days of date of debarring order to the Principal Health Secretary, Medical & Health Department, Govt. of Rajasthan who shall decide the same.

9. SAVINGS:

The debarring of particular product or supplier / firm will be done without prejudice to other penalty which may be imposed as per the conditions of tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC including respective State Drug Controllers where the supplier / company is located.

10. JURISDICTION:

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

11. EXPLANATIONS:

- (i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vis-majeure.
- (ii) The Spurious, Adulterated, Grossly sub-standard drug shall have the explanation as per guidelines issued by Govt. of India for taking action on "Not of Standard quality drugs."

 On the basis of quantitative analysis (Assay), the NOSQ drug shall be distinguished in the following manner:-

Category of NOSQ drugs	Active ingredient content (Assay)						
	Thermo stable	Thermo labile					
Minor	Up to 5% less than the prescribed	Above 70% to the prescribed					
	lower limit	lower limit					
Grossly	Below 5% of the prescribed lower	70% to 40%					
Substandard	limit to 50%						
Spurious	Below 50%	Below 40%					

- (iii) Purchase Orders, if any, already issued before taking any debarring action or replacement orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.
- (iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding tender and in case of any overlapping, the tender condition will prevail.

ANNEXURE-X (Ref. Clause: 27) FORM NO. 1 [See rule 83 of RTPP]

Memorandum of Appeal under the Rajasthan Transparency in Public Procurement Act. 2012

		Act, 2012
Ap	peal No	of
Be	fore the	(First/Second Appellate Authority)
1.	Particulars	of appellant:
	(i)	Name of the appellant:
	(ii)	Official Address, if any:
	(iii)	Residential address:
2.	Name and	address of the respondent (S):
	(i)	
	(ii)	
	(iii)	
aut om	hority who	d date of the order appealed against and name and designation of the officer/passed the order (enclose copy), or a statement of a decision, action or Procuring Entity in contravention to the provisions of the Act by which aggrieved:
		pellant proposes to be represented by a representative, the name and postal representative:
5.	Number of	f affidavits and documents enclosed with the appeal:
6. 	Ground of	appeal:
		(Supported by an affidavit)
	Prayer:	
_ u		

Appellant's Signature

RajKaj Ref 8172015

UNDERTAKING FOR EMPANELMENT

		S/oAgeProp./Partner/Director/Power of attorney
		rm M/ssituated at (Complete address of Mfg. unit
		bearing drug license on Form 25 & 28 bearing Number
		respectively, issued on datedvalid/Renewed up
to		do here by declare on oath as follows:-
	1.	That I have applied for empanelment for supply of Surgical for the item (s) I
		have quoted in the tender as enlisted in Annexure –VII
	2.	That I/We have carefully read all the conditions of Bid in Ref. no. F.02
		(175)/RMSCL/Proc./S&S (MD)/NIB-12/2024/3642 Dated:-19.06.2024 for E-BID
		supply Cum rate contract and empanelment for supply of Surgical For
		Rajasthan Medical Services Corporation and accept all conditions of Bid,
		including amendments if any.
	3.	That I will be considered empanelled for the item (s) which are declared
		technically responsive.
	4.	That I have deposited the required fees for empanelment or previous bid ref.
		no
	Dat	te Name & Signature
		with Seal

Annexure-XII (Ref. Clause No.18.2)

Supplier Consolidated Invoice

	Name of Supplier:												
Cor	nplete Ad	dress:											
E-n	nail ID:												
DL	NO.:		G	ST No	.:		I	HSN Code: Invoice No.: Date:					
Pur	chaser: M	anaging	Director			Purc	hase Or	der No.:					
	dress: Raja					Date	:						
Corporation, Gandhi-Block, Swastha Bhawan, Tilak Marg, C-Scheme, Jai													
				e, Jaip	ur								
Pho	ne No. 01	41- 2228	3066										
RM	SCL GST	'IN -08A	AFCR282	24M17	73								
	ne of Iten			2 117112		ical and	Suture	Code (R	MSC) :	• • • • • • • • • • • • • • • • • • • •			
••••		•••••			~ 8			(
S.	Name	Order	Invoic	Dat	Pa	BATC	MFG	EXP.	QUAN	Basic	Basic	GS	Total
N	of	ed	e/	e	cki	H NO.	.DT.	DT.	TITY	Rate	Amou	T	Amoun
o	DDW	Qty.	Challa		ng				Suppli	(without	nt	Am	t
			n no.		Siz				ed in	$\underline{\mathbf{GST}}$)	(witho	ount	(12+13
					e				No.		ut)
									(Batch		<u>GST</u>)		
1	2	3	4	5	6	7	8	9	wise)	11	12	13	14
					0	,			10		12	13	11
D _{an}	narke:				Total	Basic Ar	nount						
				of (%) G		ST)							
					-								
						of (%) G of (%) G							
1						_ ` /			GST, IGS	<u>T)</u>			
ı										<i>'</i>			
				Gran	d total (B	asıc An	nount + (GST Amou	ınt)				

Authorized Signatory

RajKaj Ref 8172015

Annexure-XIII (Ref. Clause No.18.2)

Analytical Report Regarding Quality

		· · · · · · · · · · · · · · · · · · ·	<u> </u>			
Name	Name of Supplier					
Add.	Add.					
PO No) .	Date:				
Surgic	al/ sutures Name					
Details	s of in house test rej	port				
S. No.	Name of Lab.	Test report No.	Date	Batch No.	Qty. Supplied	Result

Authorised Signatory

Performance Security form (Bank guarantee)

10	
Managing Director Rajasthan Medical Services Corporation WHEREAS(Name of Supplier)	Ltd
Hereinafter called "the Supplier" has undertaken, in pursuance of Contract (Let Acceptance) No	to
AND WHEREAS it has been stipulated by you in the said Contract that the Sushall furnish you a bank Guarantee from a Scheduled Bank for the sum spetherein as security for compliance with the Supplier's performance obligation accordance with the Contract.	cified
AND WHEREAS we have agreed to give the supplier a Guarantee:	
THEREFORE WE hereby affirm that we are Guarantors and responsible to yo behalf of the Supplier, up to a total of	upon said st the it of
This Bank guarantee is payable at Jaipur Branch	
This guarantee is valid until theday of2026	
Signatures and Seal	of
Guarantors Date	
Address:	
The validity of bank guarantee should be for 36 months from the date of issu	

Note:- The validity of bank guarantee should be for 36 months from the date of issuance of Bank Guarantee.

Land Border Country Registration Requirement

(To be executed on a non-judicial stamp paper valued Rs. 50/-)
Name of BidderNIB Number
I/We have read the Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021 regarding Provisions for Procurement from a Bidder which shares a land border with India, I/we certify that, bidder M/s(Name of Bidder) is
(i) not from such a country
or
(ii) if from such a country has been registered with the Authority i.e. as specified in Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021. (Evidence of valid registration by the Authority shall be attached).
(Bidder to select one option
Name: [insert complete name of person signing the bid]
In the capacity of [insert legal capacity of person signing the bid]

Signed: [insert signature of person whose name and capacity are shown above]

Duly authorized to sign the Bid for and on behalf of [insert complete name of the bidder]

Performance Security Declaration (To be executed on a non-judicial stamp)

Date:[insert date (as day, month and year)]
Contract Name and No.:[insert name and number of Contract]
To:[insert Designation and complete address of Procuring
Entity]
We, the undersigned, declare that we are a (Strike out which is not applicable. Please enclos an authentic certificate issued by the Administrative Department of respective government under which the bidder entity is constituted.):
(i) Departments/Boards of the State Government or Central Government; or
(ii) Government Companies as defined in clause (45) of section 2 of the Companies Act, 2013; or
(iii) Company owned or controlled, directly or indirectly, by the Central Government, or by an State Government or Governments, or partly by the Central Government and partly by one of more State Governments which is subject to audit by the Auditor appointed by the Comptrolled and Auditor-General of India under sub-section (5) or (7) of section 139 of the Companies Act 2013; or
(iv) Autonomous bodies, Registered Societies, Cooperative Societies which are owned or controlle or managed by the State Government or Central Government.
or managea by the State Government or Central Government. We understand that we are eligible for submission of a Performance Securing Declaration in lieu of Performance Security under Rule 75 (1) of RTPP Rules, 2013
We understand that, according to your conditions, the Contract must be supported by a Performanc Security Declaration as a guarantee to ensure fulfillment of our all performance obligations under the
Contract for[insert name of subject matter of procurement]
We accept that we will automatically be suspended from being eligible for bidding in any contract
with you for the period of time of[Procuring Entity to indicate here the period of
time for which the Procuring Entity will declare a Bidder in eligible to be awarded a Contract
the performance Security Declaration is to be executed] starting on the date that we receive
notification from you, the[Designation of the Procuring Entity] that or
Performance Security Declaration is executed, if we are in breach of any of our performance
obligation under the conditions of the Contract,
We understand this Performance Security Declaration shall expire after 60 days of completion of ou
all obligations under the Contract including Defect Liability, warranty/ Guarantee, operation
maintenance, etc. in accordance with the conditions of the Contract.
Signed: [insert signature of person whose name and capacity are shown]
In the capacity of:[insert legal capacity of person signing the Performance Securit
Declaration
Name:[insert complete name of person signing the Declaration]
Duly authorized to sign the Contract for and on behalf of:[insert complete name an
address of the Bidder
Dated onday of[insert date of signing]
Corporate Seal

NO DEVIATION DECLARATION

[To be given on letterhead]

Ref. No.: _____

S. No.	Item Code (as mentioned in annexure- VII)	n of item (s)	Specification of item (s) as per bidder	Deviation with respect to specifications No/Yes (if yes, than specify)
Date : Place :				fame : ignature of Bidder:
		Seal of the		
			В	usiness Address :

BIDDER'S AUTHORIZATION CERTIFICATE

To, {Procuring entity},,
I/ We {Name/ Designation} hereby declare/ certify that {Name/ Designation and contact no. with mail id} is hereby authorized to sign relevant documents on behalf of the company/ firm in dealing with NIB reference No. dated He/ She is also authorized to attend meetings & submit technical & commercial information/ clarifications as may be required by you in the course of processing the Bid. For the purpose of validation, his/ her verified signatures are as under.
Thanking you,
Name of the Bidder: - Verified Signature: Authorized Signatory: - Seal of the Organization: - Date: Place: